Modulation of T Cell Signaling Threshold and T Cell Sensitivity to Antigens

ABSTRACT

MicroRNAs (miRNAs) are a diverse and abundant class of ˜22-nucleotide (nt) endogenous regulatory RNAs that play a variety of roles in animal cells by controlling gene expression at the posttranscriptional level. Increased miR-181a expression in mature T cells is shown to cause a marked increase in T cell activation and augments T cell sensitivity to peptide antigens. Moreover, T cell blasts with higher miR-181a expression become reactive to antagonists. The effects of miR-181a on antigen discrimination are in part achieved by dampening the expression of multiple negative regulators in the T cell receptor (TCR) signaling pathway, including PTPN22 and the dual specificity phosphatases DUSP5 and DUSP6. This results in a reduction in the TCR signaling threshold, thus quantitatively and qualitatively enhancing T cell sensitivity to antigens.

GOVERNMENT SUPPORT

This invention was made with support from the National Institutes ofHealth, grant nos. 1ROI HL081612-01 and 5ROI AI022511. The Governmenthas certain rights in this invention.

BACKGROUND OF THE INVENTION

One of the key features of a functioning immune system is its ability todistinguish antigens of foreign origin from those derived endogenouslyand to mount an immune response against the former. With respect to Tcells, this goal is achieved through antigen recognition by T cellreceptors (TCRs) and a highly ordered developmental process in thethymus and in secondary lymphoid organs. TCRs constantly sample diverseself- or foreign-peptide antigens presented in major histocompatibilitycomplexes (MHCs) on the surface of antigen presenting cells (APCs) andelicit discrete intracellular signals and T cell responses. The mature Tcell's response to antigens is largely dictated by the bindingcharacteristics of its TCR for a given peptide-MHC complex. In general,peptide-MHC (pMHC) ligands with slower dissociation rates producestronger TCR signals and lead to higher T cell reactivity to theantigenic peptides.

Variations in the antigenic peptide affinities to TCRs may lead to bothquantitative and qualitative changes in its ability to activate TCRsignaling pathways and T cell responses. Typically, the most stable pMHCcomplexes with respect to TCR binding are agonists, while the lessstable variants are weak agonists and then antagonists, which are notable to activate T cells more than partially themselves and also blockthe response to agonist ligand. Although a number of models have beenproposed to explain the kinetic discrimination in T cell activation,exactly how T cells sense quantitative changes in antigenic peptideaffinities through their TCRs and produce both quantitatively andqualitatively different responses remains an intensive area of study.

In addition, T cell responsiveness and TCR signaling to a specificligand also vary with different developmental stages, suggesting that Tcell sensitivity to antigens might be intrinsically regulated duringdevelopment. For example, in immature CD4+CD8+ double positivethymocytes, low affinity antigenic peptides that are unable to activatemature effector T cells are sufficient to induce strong activation andclonal deletion; antagonists that are normally inhibitory to effector Tcells can induce positive selection. These observations demonstrate thatT cell sensitivity is intrinsically regulated to ensure the properdevelopment of specificity and sensitivity to foreign antigens whileavoiding self-recognition. However, little is known about how intrinsicmolecular programs are regulated, and how they influence T cellsensitivity toward antigens.

Methods of regulating T cell signaling thresholds and sensitivity toantigens is of great interest for clinical and research purposes. Thepresent invention provides a means to regulate these functions.

Publications:

MicroRNAs (miRNAs) are an abundant class of non-coding RNAs that arebelieved to be important in many biological processes through regulationof gene expression. These ˜22-nt RNAs can repress the expression ofprotein-coding genes by targeting cognate messenger RNAs for degradationor translational repression. The mechanisms by which miRNAs exert theseeffects are unclear, as is whether they have any specific role in theadaptive immune response.

Chen et al. (2004) Science 303:83 describe the modulation ofhematopoietic lineage differentiation by microRNAs. Krutzfeldt et al.(2005) Nature 438:685 describe the silencing of microRNAs in vivo withantagomirs.

The miR-181a RNA is represented in published US Patent Applications:20060185027, Systems and methods for identifying miRNA targets and foraltering miRNA and target expression; 20060134639, Method for thedetermination of cellular transcriptional regulation; 20060105360,Diagnosis and treatment of cancers with microRNA located in or nearcancer associated chromosomal features; 20060099619, Detection andquantification of miRNA on microarrays; 20060057595, Compositions,methods, and kits for identifying and quantitating small RNA molecules;20060019286, High throughput methods relating to microRNA expressionanalysis; 20050261218, Oligomeric compounds and compositions for use inmodulation small non-coding RNAs; 20050260648, Method for thedetermination of cellular transcriptional; 20050256072, Dual functionaloligonucleotides for use in repressing mutant gene expression.

SUMMARY OF THE INVENTION

Methods and compositions are provided for regulating T cell signalingthreshold and T cell sensitivity to antigen by modulating expression ofa microRNA rheostat. Target cells and tissues of interest for modulationinclude bone marrow, e.g. stem cells, lymphocyte progenitor cells, etc.;thymocytes; peripheral blood, e.g. T helper cells, cytotoxic T cells,memory T cells, regulatory T cells, and the like. By altering thesignaling threshold with respect to an antigen of interest, the T cellmediated immune response can be tailored to provide for increasedresponsiveness, e.g. against antigens associated with tumors, chronicinfections, etc.; or to provide for decreased responsiveness, e.g.against allergens, autoantigens, transplantation antigens, etc.

In one embodiment of the invention, miR-181a and the targets of miR-181aas described herein are used in the screening of candidate agents foractivity in regulation of T cell signaling threshold and T cellsensitivity to antigen. Embodiments of interest include screening foragents that act on at least two or more of the pathways regulated bymiR-181a.

In other embodiments, the genetic sequence encoding miR-181a, and/or theexpression levels of miR-181a are determined in connection withdiagnostic applications, where alterations in the sequence or level ofexpression are correlated with aberrations in the regulation of T cellsignaling threshold and T cell sensitivity to antigen.

It is shown herein that increasing expression of the microRNA miR-181ain T cells quantitatively augments the output of T cell receptorsignaling, as indicated, inter alia, by the elevation of intracellularcalcium, cytokine production, and cell proliferation. Accompanying theincrease in T cell sensitivity to antigen, these cells can also becomereactive to peptide antigens that are otherwise incapable of activatingT cells, and which may otherwise block T cell activation. The change inreactivity to peptide antigens is attributable in part to selectivedown-regulation of multiple negative regulatory proteins, including theERK specific dual specificity phosphatases DUSP5 and DUSP6. In someembodiments of the invention, the T cell signaling threshold and T cellsensitivity to antigen is achieved by modulation of DUSP5 and/or DUSP6activity.

Increasing miR-181a expression in T cell blasts results in decreasedphosphatase levels, which leads to an increase in the amount ofactivated Lck and ERK kinases without antigenic stimulation and areduction in the threshold required for T cell activation. In addition,the surface densities of costimulatory molecules CD28 and CTLA-4 arechanged. These results demonstrate that miR-181a controls multiplepathways that regulate the sensitivity of T cells to antigen. Byreducing negative feedback mechanisms and potentiating positive ones, Tcells are manipulated to exhibit quantitatively and qualitativelydifferent responses to antigen stimulation.

These and other embodiments of the invention will be apparent from thedescription that follows. The compositions, methods, and techniquesdescribed in this disclosure hold considerable promise for use indiagnostic, drug screening, and therapeutic applications.

BRIEF DESCRIPTION OF THE FIGURES

The patent or application file contains at least one drawing executed incolor. Copies of this patent or patent application publication withcolor drawing(s) will be provided by the Office upon request and paymentof the necessary fee.

FIG. 1A-1F Effects of miR-181a on agonist stimulated T cell calciumresponse. (A) Developmental regulation of miR-181a expression in variouspurified T cell populations determined by RT-PCR. (B) qPCR analysis ofmiR-181a ectopic expression in effector T cell blasts. (C & D), Calciumflux in T cells ectopically expressing control virus (C) or miR-181avirus (D) in response to defined number of agonist MCC peptide. Topleft, the peptide images representing the integrated intensity of 6 MCCpeptides at the T cell and APC (T:APC) interface. Bottom left, relativecytosolic calcium concentration as a function of time after stimulation,as measured from ratioed fura-2 images; the arrow indicates the timepoint at which the peptide image (shown in top left) was taken. Topright, overlaid differential interference contrast (DIC) images andratioed calcium images taken at different time points after stimulation.Bottom right, corresponding ratioed calcium images. Fluorescenceintensity of calcium signal is represented in a false color scale. (E)Integrated calcium signals as a function of defined number of MCCligands. Ratioed calcium images were measured every 15 seconds inresponding T cells and integrated for 5 minutes from the time of initialcalcium increase. Each data point represents the average calcium signalsof three or more responding T cells. Lines are fitted with the samesigmoidal dose-response (variable slope) equation. The dashed linesindicate the number of peptides required to reach half maximal calciumresponses. The double arrow illustrates the absolute increase of calciumsignal plateau. (F) Effects of miR-181a on T cell calcium responses toAPCs preloaded with various concentrations of the weak agonist MCC 102S(averaged integrated calcium value±SD, n=30). All calcium responsecurves (C-F) are color-coded for control (blue) or miR-181a (red) T cellblasts.

FIG. 2A-2F Effects of miR-181a on antagonist function. (A & B) OverlaidDIC and calcium ratio images taken at various time points after thecontrol (top panel) or the miR-181a T cell blasts (lower panel) werestimulated with APCs preloaded with (A) mixed agonist MCC (0.1 μM) andantagonist MCC 99R (20 μM) or (B) antagonist MCC 99R (20 μM) alone. (C)Average calcium level was plotted against time. Each data pointrepresents the average calcium level of 30 or more responding T cells ineach of the experimental groups. Time zero was designated as the imagestack before the first 20% calcium increase for the miR-181a T cellblasts or the frame of initial T:APC contact in the DIC channel fornon-responding T cells. (D) Induction of IL-2 production by antagonistMCC 99R. Virally-infected and selected T cell blasts were set to rest byday 10 after preparation, then co-cultured with γ-irradiated CH27 cellspreloaded with either the null peptide MCC 99A (10 μM), the antagonistMCC 99R (10 μM), or the agonist MCC (1 μM). Supernatants were collectedat 24 hours after stimulation and analyzed for IL-2 production by ELISA([IL-2]±SD, n=3). (E) Induction of T cell proliferation by theantagonist MCC 99R. Virally-infected and selected T cell blasts werestained with the fluorescent dye CFSE and co-cultured with γ-irradiatedCH27 cells preloaded with null peptide MCC 99A (10 μM), antagonist MCC99R (10 μM), or agonist MCC (1 μM) on day 12 after preparation. T cellswere harvested and analyzed by FACS 24 hours after co-culture.Percentage of T cells undergoing proliferation was calculated asdescribed (Gudmundsdottir et al., 1999). Representative experiments ofthree independent analyses are shown. (F) Effects of miR-181a on T cellcalcium responses to the antagonist 102G. Virally-infected T cell blastswere stimulated with APCs preloaded with various concentrations of theantagonists MCC 99R and 102G (fura ratio±SD, n=30).

FIGS. 3A-3C MiR-181a represses multiple phosphatases in T cell blasts.(A) Effects of miR-181a and miR-181a^(mut) expression on luciferasereporter constructs containing putative miR-181a target sites are shownas the relative luciferase activity (normalized to the Rennilla controland compared to the control reporter vector). Representative analyses offour independent experiments are shown (relative luciferase activity±SD,n=3; Student's t test, **: P<0.01). (B) MiR-181a regulation ofphosphatase expression at the protein level. Western blot analyses wereperformed to determine the protein levels of SHP-1, SHP-2, PTPN22, DUSP6and DUSP5 in T cells ectopically expressing either the control virus,miR-181a, or miR-181a^(mut) virus. Membranes were stripped and re-probedwith anti-β-actin as a loading control. Relative protein expressionlevels were determined by densitometry and normalized to the loadingcontrols. (C) Effects of miR-181a on its target messenger RNA levels inT cell blasts were determined by qPCR analyses and indicated as relativeexpression level (normalized to β-actin and compared to the levels inthe control T blast).

FIGS. 4A-4E MiR-181a increases the basal level phosphorylation ofdownstream TCR signaling molecules. (A) Western blot analyses ofanti-Lck immuno-precipitates to detect site-specific phosphorylation.Phosphorylation of Lck at the activating Y394 or inhibitory Y505 beforeantigen stimulation were probed with specific antibodies. Lckphosphorylation was also analyzed in the miR-181a T cell blasts withrestored DUSP6 or SHP-2 expression. Membranes were stripped andre-probed for Lck as loading controls. (B) Induction of ERKphosphorylation by the antagonist MCC 99R. Virally-infected T cells weremixed with CH27 cells alone or CH27 cells preloaded with 10 μM MCC 99R,spun down to facilitate rapid T:APC contact, incubated at 37° C. for 5minutes, and analyzed for ERK phosphorylation by Phosphor-Flow. Cellswere gated on GFP and CD4 for virally-infected T cells. (C) Effects ofmiR-181a on the kinetics of ERK phosphorylation upon T cell stimulationby anti-CD3ε cross-linking according to Phospho-Flow analysis. (D)Western blot analyses of anti-Lck immuno-precipitates to detect Lckserine phosphorylation before antigen stimulation. (E) MiR-181aexpression inhibits the Lck and SHP-1 interaction. Double selected 5C.C7T cells were mixed with peptide pre-loaded CH27 cells (10 μM MCC 99R or1 μM MCC) by quick spin and incubated at 37° C. for 5 mins. SHP-1 wasco-precipitated with Lck whereas SHP-2 was undetectable under the samecondition.

FIGS. 5A-5C shRNAs against individual miR-181a targets cannot fullyrecapitulate miR-181a function. (A&B) The efficacy and specificity ofshRNA constructs that were designed to target DUSP6, SHP-2, SHP-1, andDUSP5, respectively, as determined by Western-blot analyses. (C) Calciumresponses to antagonist MCC 99R stimulation in T cell ectopicallyexpressing miR-181a or shRNAs against individual miR-181a targets,DUSP6, DUSP5, SHP-2, or SHP-1, respectively. Both the strength ofcalcium response and percentage of T cells activated were measured andsummarized. Integrated calcium flux during the first 5 minutes afteractivation was used to evaluate the strength of TCR signaling. T cellswith continuous calcium elevation at 50% above the baseline (designatedas 1) for one minute were designated as activated T cells. Integratedcalcium ratio was arbitrarily categorized using the response of thecontrol T cell blasts to the agonist MCC as a reference and shown incolor codes (<2, no response; 2-8.0, weak response; 8.0-12.0, mediumresponse; >12.0, strong response).

FIGS. 6A-6E Restoring individual targets abrogates miR-181a effects on Tcell sensitivity. (A) Western blot analysis shows restored DUSP6expression. Abolishing T cell reactivity to the antagonist MCC 99R byrestoring DUSP6 expression in miR-181a T cell blasts. (B) RestoringDUSP6 expression is sufficient to override the effects of miR-181a onthe basal level and the post-stimulation kinetics of ERKphosphorylation. The gray line marks the basal level of ERK activationin control cells and the brown line indicates the full activation levelof ERK in control T cells upon TCR activation. (C) Overlaid DIC andcalcium ratio images taken at various time points after T cellsectopically expressing miR-181a alone (top panel) or miR-181a and DUSP6together (lower panel) were stimulated with APCs preloaded withantagonist MCC 99R (20 μM). (D) Cytosolic calcium concentration as afunction of time in T cells ectopically expressing control virus (grey),miR-181a alone (red), miR-181a and DUPS6 (dark blue line), miR-181a andwild type DUSP5 (green line), miR-181a and NLS mutated DUSP5 (lightblue), and miR-181a and SHP-2 (purple). (E) Effects of individual targetrestoration on IL-2 production. Virally infected and selected T cellblasts were set to rest by day 12 after initial preparation, thenco-cultured with γ-irradiated CH27 cells preloaded with either the nullpeptide MCC 99A (20 μM), the antagonist MCC 99R (10 μM), or MCC 102G (20μM). Supernatants were collected at 24 hours after stimulation andanalyzed for IL-2 production by ELISA ([IL-2]±SD, n=3).

FIGS. 7A-7B. Reducing miR-181a expression dampens T cell sensitivity toantigens in naïve T cells. Naïve T cells isolated from the lymph nodesof 5C.C7 TCR transgenic mice on the Rag2−/− background were transfectedwith 50 μg/ml antagomir-181 (Ant181) or its mismatch control (MmAnt181), and cultured for 16 hours in the presence of 5 ng/ml IL-7before antigen stimulation. CH27 cells were loaded with variousconcentrations of agonist MCC or weak agonist MCC 102S and served asAPC. T cell responses were measured by (A) calcium imaging or (B) IL-2ELISA. (A) Effects of antagomir-181a on calcium responses (averagedintegrated calcium value±SEM, n=30); (B) Effects of antagomir-181a onIL-2 production ([IL-2]±SD, n=3). T cells were stimulated byco-culturing with γ-irradiated CH27 cells preloaded with antigenicpeptide at a serial titration. Supernatants were collected 24 hoursafter stimulation.

FIGS. 8A-8D. MiR-181a controls thymocyte selection. (A) MiR-181acontrols DP thymocyte negative selection. Fetal thymic organ cultureswere established from e17 5C.C7 TCR transgenic mouse embryos on an li−/−B10BR background. Antagomir-181a (50 μg/ml) or the mock control wasapplied right after the initiation of the culture. 100 nM MCC, 5 μM MCC99R or PBS control was introduced 24 hours after antagomir treatment.Single cell suspensions were prepared from cultured thymi 48 hours afterpeptide application. Data illustrated here represent 6 replicatedexperiments. (B) MiR-181a controls DP thymocyte positive selection. FTOCwas performed with thymi dissected from e15 or e16 5C.C7 wild typeembryos (absent of SP cell) and antagomir-181a (50 μg/ml) or the mockcontrol was applied right after the initiation of culture. Thymocyteswere collected after 4-5 days and stained for CD4 and CD8 todiscriminate thymocyte populations. CD69 and CD62L stainings were alsoperformed to verify the post-selection phenotype of SP cells. Dataillustrated here represent 6 replicated experiments. (C) Antagomir-181aimpairs DP cell responsiveness to antigen. DP cells were prepared fromthe thymus of adult 5C.C7 li−/− mice and pretreated with Cy3 labeledantagomir-181a at various concentrations for 12 hours. CH27 cells servedas APC after loading with 0.5 μM MCC (solid line), 0.5 μM MCC 1025(dotted line) or PBS as a control (grey line). DP cells and APCs werecocultured for 3 hours then stained for CD4, CD8 and the T cell earlyactivation marker CD69. Left panel, dose-dependent uptake ofantagomir-181a in DP cells; right panel, the responsiveness of DP cellsrepresented by surface CD69 elevation. (D) Antagomir-181a inhibits ERKactivation in DP thymocytes. DP cells were prepared from the thymus ofadult 5C.C7 li−/− mice and pretreated with 50 μg/ml antagomir-181a for12 hours. CH27 cells served as APC after loading with 10 μM MCC 99R orPBS alone (grey line). The kinetics of ERK phosphorylation was probed asdescribed in FIG. 4C.

FIGS. 9A-9B Schematics of the miR-181a T cell sensitivity rheostat. (A)Molecular targets of miR-181a that controls TCR signaling threshold andT cell sensitivity. (B) A model for tuning TCR signaling threshold and Tcell sensitivity to antigens. Selected signaling components aredepicted.

FIG. 10. qPCR analysis of developmental regulation of miR-142 expressionin various purified T cell populations.

FIGS. 11A-11C. Schematics of miRNA and shRNA expression constructs (A),luciferase reporter constructs (B), and target restoring vectors (C).

FIGS. 12A-12B. A miR-181a mutant with dramatically reduced activity inaugmenting TCR signaling strength. (A) Schematic representation of thewild-type (SEQ ID NO:1) and the mutant (SEQ ID NO:2) miR-181a precursor.The 5′ 2nd and 3rd nucleotides of the mature miR-181a sequence werealtered. Compensatory mutations were introduced into the precursor topreserve the secondary structure of pre-miR-181a. (B) 5C.C7 T cellblasts expressing control, miR-181a, or a miR-181a null mutant werestimulated with CH27 APCs preloaded with 0.1 of the agonist MCC. Calciumresponse of individual T cells was recorded by multichannelvideo-microscopy and analyzed with MetaMorph software. 40 cells fromeach group were randomly selected and the integrated increases incytosolic calcium concentration were scored for the first 5 minutes ofthe reaction. Err bar: SD.

FIGS. 13A-13D. (A & B) Effects of miR-181a expression on various T cellsurface molecule expression. (A) Surface expression of 5C.C7 TCR and CD4coreceptor on the miR-181a T cell blasts. Day 6 5C.C7 T cellsectopically expressing miR-181a, miR-142, or control virus were stainedwith antibodies against 5C.C7 TCR (anti-Vβ3-PE) and CD4 coreceptor(anti-CD4-PE-Cy5), and analyzed by flow cytometry. Histograms show theVβ3 TCR or CD4 fluorescence intensity of the GFP⁺ and CD4^(high) cells.(B) Surface expression of the costimulation molecules CD28 and CTLA-4 onthe miR-181a T cell blasts. T cell blasts were stained with antibodiesagainst CTLA-4 (PE), CD4 (PE-Cy5), and CD28 (PE-Cy7), and analyzed byflow cytometry. Histograms show the CD28 and CTLA-4 fluorescenceintensities of the GFP⁺ and CD4^(high) populations. Representativehistograms of four independent experiments are shown in (A) and (B). (C& D) Effects on the costimulation pathway may in part contribute to theincreased TCR signal strength in the miR-181a T cell blasts. 5C.C7 Tcells ectopically expressing either miR-181a or control virus wereactivated by anti-CD3ε cross-linking or anti-CD3ε and CD28 doublecross-linking. T cells were first incubated with either biotin-anti-CD3ε(10 μg/ml) and biotin-syrian hamster IgG control (10 μg/ml), orbiotin-anti-CD3ε (10 μg/ml) and biotin-anti-CD28 (10 μg/ml). Calciumresponse was monitored with video-microscopy after adding streptavidin(2 μg/ml) to cross-link the TCR alone or TCR plus CD28. 30 T cells wererandomly selected from each experimental group and the averagedintracellular calcium concentration was plotted as a function of time(C) and the integrated calcium responses during the first 5 minutes ofstimulation are shown (D).

FIGS. 14A-14C. The effect of miR-181a on antagonist to agonistconversion is independent of its effects on the costimulation pathway.CH27 APCs preloaded with the antagonist MCC 99R (10 μM) were incubatedwith anti-B7.1 (10 μg/ml) and anti-B7.2 (10 μg/ml) at room temperaturefor 20 minutes to block the costimulation pathway and then used tochallenge miR-181a T cell blasts for calcium image analysis. (A)Representative movie montages show that miR-181a T cell blasts react tothe antagonist MCC 99R in the presence of costimulation blockade. DIC(top panel) and corresponding ratioed calcium images (bottom panel)taken at different time points after stimulation are shown. Fluorescenceintensity of calcium signal is represented in a false color scale. (B)Average calcium level is plotted again time. Each data point representsthe average calcium level of 30 responding T cells in each experimentalgroup. (C) Integrated calcium responses during the first 5 minutes ofstimulation are shown.

FIGS. 15A-15D. Alignment of miR-181a with predicted target sites fromPTPN22 (A) SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO7, SEQ ID NO 8; SHP-2 (B) SEQ ID NO 9, DUSP6 (C) SEQ ID NO 10, SEQ ID NO11, SEQ ID NO 12, and DUSP5 (D) SEQ ID NO 13, SEQ ID NO 14, SEQ ID NO15.

FIG. 16. Calcium responses to the antagonist MCC 99R in T cell blastsectopically expressing shRNAs targeting individual miRNA-181a targets.Average calcium level was plotted again time. Each curve represents theaverage calcium level of 30 or more T cells in each experimental group.Only those T cells with medium to strong calcium responses (>8.0) areshown.

FIGS. 17A-17B. Effects of restoring individual target gene expression inthe miR-181a T cell blasts on T cell reactivity to the antagonist MCC99R. (A) Western-blot analysis of DUSP5-GFP expression in the miR-181a Tcell blasts. Infected T cells were selected for blasticidin resistanceand lysed at day 6 for Western blot analysis. Relative DUSP5 expressionlevel was determined by densitometry and normalized to the actin loadingcontrol. (B) Western-blot analysis of SHP-2-GFP fusion proteinexpression in the miR-181a T cell blasts. DUSP5 and SHP-2 expression wasrestored by co-expression of miR-181a and the SHP-2-GFP fusion proteinin the above-described vector described.

FIGS. 18A-18C. Knocking-down miR-181a expression reduces T cellsensitivity to antigens in primed T cell blasts. (A) FACS analysis ofantagomir uptake in T cell blasts. T cell blasts were transfected with5′ Cy3 labeled antagomir-181a or its mismatch control (50

?g/ml). Cells were gated on CD4 positive and analyzed at Cy3 channel. (B& C) Effects of antagomir-181a on calcium responses (B) and IL-2production (C) in mature T cell blasts stimulated with APCs preloadedwith various concentrations of agonist MCC or weak agonist MCC 102S(averaged integrated calcium value±SEM, n=30; [IL-2]±SD, n=3). T cellblast responses to antigens were quantified by calcium flux or IL-2secretion at 16 hours after antagomir transfection.

FIG. 19. Antagomir design with and without reporter group Cy3 (Quasar570) or Cy5 (Quasar 670) at the 5′-end.

DETAILED DESCRIPTION OF THE EMBODIMENTS

Methods and compositions for altering T cell signaling threshold andsensitivity in a target cell are provided. In the subject methods, theactivity of a miRNA is modulated. In some embodiments, the amount of thetargeted miRNA in the target cell is reduced, e.g., by introducing amiRNA inhibitory agent in the target cell, thereby increasing the T cellsignaling threshold in the targeted cell. In another embodiment, theamount of the targeted miRNA in a cell is increased, e.g. by introducingmiRNA or an miRNA expression vector in the target cell, therebydecreasing the T cell signaling threshold in the target cell. Alsoprovided are pharmaceutical compositions, kits and systems for use inpracticing the subject methods. The subject invention finds use in avariety of applications, including the treatment of subjects sufferingfrom undesirable T cell activity, e.g. in autoimmune diseases, graftrejection, allergic responses, etc.; and in subjects suffering frominadequate T cell activity, e.g. in directing immune responses tochronically infected cells, to tumor cells, and the like.

Before the present invention is further described, it is to beunderstood that this invention is not limited to particular embodimentsdescribed, as such may, of course, vary. It is also to be understoodthat the terminology used herein is for the purpose of describingparticular embodiments only, and is not intended to be limiting, sincethe scope of the present invention will be limited only by the appendedclaims.

Where a range of values is provided, it is understood that eachintervening value, to the tenth of the unit of the lower limit unlessthe context clearly dictates otherwise, between the upper and lowerlimit of that range and any other stated or intervening value in thatstated range, is encompassed within the invention. The upper and lowerlimits of these smaller ranges may independently be included in thesmaller ranges and are also encompassed within the invention, subject toany specifically excluded limit in the stated range. Where the statedrange includes one or both of the limits, ranges excluding either orboth of those included limits are also included in the invention.

Methods recited herein may be carried out in any order of the recitedevents which is logically possible, as well as the recited order ofevents.

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. Although any methods andmaterials similar or equivalent to those described herein can also beused in the practice or testing of the present invention, the preferredmethods and materials are now described.

All publications mentioned herein are incorporated herein by referenceto disclose and describe the methods and/or materials in connection withwhich the publications are cited.

It must be noted that as used herein and in the appended claims, thesingular forms “a”, “an”, and “the” include plural referents unless thecontext clearly dictates otherwise. It is further noted that the claimsmay be drafted to exclude any optional element. As such, this statementis intended to serve as antecedent basis for use of such exclusiveterminology as “solely,” “only” and the like in connection with therecitation of claim elements, or use of a “negative” limitation.

The publications discussed herein are provided solely for theirdisclosure prior to the filing date of the present application. Nothingherein is to be construed as an admission that the present invention isnot entitled to antedate such publication by virtue of prior invention.Further, the dates of publication provided may be different from theactual publication dates which may need to be independently confirmed.

As summarized above, the subject invention provides methods andcompositions modulating T cell signaling threshold and T cellsensitivity to antigen. In further describing the subject invention, thesubject methods are described first in greater detail, followed by areview of various representative applications in which the subjectinvention finds use as well as kits that find use in practicing thesubject invention.

General methods in molecular and cellular biochemistry can be found insuch standard textbooks as Molecular Cloning: A Laboratory Manual, 3rdEd. (Sambrook et al., Harbor Laboratory Press 2001); Short Protocols inMolecular Biology, 4th Ed. (Ausubel et al. eds., John Wiley & Sons1999); Protein Methods (Bollag et al., John Wiley & Sons 1996); NonviralVectors for Gene Therapy (Wagner et al. eds., Academic Press 1999);Viral Vectors (Kaplift & Loewy eds., Academic Press 1995); ImmunologyMethods Manual (I. Lefkovits ed., Academic Press 1997); and Cell andTissue Culture: Laboratory Procedures in Biotechnology (Doyle &Griffiths, John Wiley & Sons 1998). Reagents, cloning vectors, and kitsfor genetic manipulation referred to in this disclosure are availablefrom commercial vendors such as BioRad, Stratagene, Invitrogen,Sigma-Aldrich, and ClonTech.

The present invention has been described in terms of particularembodiments found or proposed by the present inventor to comprisepreferred modes for the practice of the invention. It will beappreciated by those of skill in the art that, in light of the presentdisclosure, numerous modifications and changes can be made in theparticular embodiments exemplified without departing from the intendedscope of the invention. For example, due to codon redundancy, changescan be made in the underlying DNA sequence without affecting the proteinsequence. Moreover, due to biological functional equivalencyconsiderations, changes can be made in protein structure withoutaffecting the biological action in kind or amount. All suchmodifications are intended to be included within the scope of theappended claims.

MicroRNAs (miRNAs) are an abundant class of non-coding RNAs that arebelieved to be important in many biological processes through regulationof gene expression. These noncoding RNAs that can play important rolesin development by targeting the messages of protein-coding genes forcleavage or repression of productive translation. Humans have between200 and 255 genes that encode miRNAs, an abundance corresponding toalmost 1% of the protein-coding genes.

MicroRNAs of interest for use in the methods of the invention includethose natural RNAs expressed in cells of the immune system. For example,see Min and Chen (2006) Methods Mol. Biol. 342:209-27 for methods andstrategies for dissecting miRNA function during hematopoietic lineagedifferentiation. Chowdhury and Novina (2005) Adv Immunol. 88:267-92,describe RNAi and RNA-based regulation of immune system function.Chowdhury and Novina (2005) Immunol Cell Biol. 83(3):201-10 discusspotential roles for short RNAs in lymphocytes. Each of these referencesis herein specifically incorporated by reference for the teaching ofmicroRNAs expressed in cells of the immune system, and for the specificmicroRNAs disclosed.

miR-181a has been identified as one of three miRNAs that arespecifically expressed in hematopoietic cells, with expressiondynamically regulated during early hematopoiesis and lineage commitment.The role of miR-181 in the B-lymphoid cells has been described by Chenet al., supra. miR-181 is very strongly expressed in the thymus, theprimary lymphoid organ, which mainly contains T lymphocytes. It is alsostrongly expressed in the brain and lung and is detectable in bonemarrow and the spleen. Mature miR-181 expression has been reported inbone marrow cells and up-regulated in differentiated B lymphocytes,which are marked by the B220 surface antigen.

The nucleotide sequence of representative miR-181a sequences is providedin Table 1. It can be seen that the sequence is very highly conservedamong primate and mammalian species.

TABLE 1 miR-181a Sequences Genbank organism accession DNA sequenceRNA sequence Bos Taurus DQ274916 SEQ ID NO: 16 SEQ ID NO: 17aacattcaacgctgtcggtgag aacauucaacgcugucggugag Macaca nemestrina AY866169SEQ ID NO 18 SEQ ID NO 19 aacattcaacgctgtcggtgag aacauucaacgcugucggugagSaguinus labiatus AY866168 SEQ ID NO 20 SEQ ID NO 21aacattcaacgctgtcggtgag aacauucaacgcugucggugag Macaca mulatta AY866167SEQ ID NO 22 SEQ ID NO 23 aacattcaacgctgtcggtgag aacauucaacgcugucggugagPan troglodytes AY866166 SEQ ID NO 24 SEQ ID NO 25aacattcaacgctgtcggtgag aacauucaacgcugucggugag Pan paniscus AY866165SEQ ID NO 26 SEQ ID NO 27 aacattcaacgctgtcggtgag aacauucaacgcugucggugagGorilla gorilla AY866164 SEQ ID NO 28 SEQ ID NO 29aacattcaacgctgtcggtgag aacauucaacgcugucggugag Homo sapiens SEQ ID NO 30SEQ ID NO 31 aacattcaacgctgtcggtgagt aacauucaacgcugucggugaguMus musculus AJ560723 SEQ ID NO 32 SEQ ID NO 33 aacattcaacgctgtcggtgagtaacauucaacgcugucggugagu

As used herein, the term miR-181a may refer to any of the providedsequences, usually in reference to a 22 or 23 nucleotide polynucleotidecomprising the sequence aacattcaacgctgtcggtgag. Included in the scope ofthe term “microRNA” is included synthetic molecules with substantiallythe same activity as the native microRNA, e.g. syntheticoligonucleotides having altered chemistries, as are known in the art.

In practicing the subject methods, an effective amount of a miR181aagent is introduced into the target cell, where any convenient protocolfor introducing the agent into the target cell may be employed. Thetarget cell is usually a cell of the T lymphocyte lineage, including,without limitation, hematopoietic stem cells, committed lymphocyteprogenitors, pro-T cells, pre-T cells, thymocytes, mature T cells, andmemory T cells. Mature T cells include th1 helper T cells, th2 helper Tcells, th3 helper T cells, cytotoxic T cells, natural killer T cells(NKT cells), T regulatory cells, and the like.

The subject methods are used for prophylactic or therapeutic purposes.As used herein, the term “treating” is used to refer to both preventionof disease, and treatment of pre-existing conditions. For example, theprevention of autoimmune disease may be accomplished by administrationof the agent prior to development of overt disease. The treatment ofongoing disease, where the treatment stabilizes or improves the clinicalsymptoms of the patient, is of particular interest.

As is known in the art, miRNAs are single stranded RNA molecules thatrange in length from about 20 to about 25 nt, such as from about 21 toabout 24 nt, e.g., 22 or 23 nt. The target miR181a may or may not becompletely complementary to the introduced miR181a agent. If notcompletely complementary, the miRNA and its corresponding target viralgenome are at least substantially complementary, such that the amount ofmismatches present over the length of the miRNA, (ranging from about 20to about 25 nt) will not exceed about 8 nt, and will in certainembodiments not exceed about 6 or 5 nt, e.g., 4 nt, 3 nt, 2 nt or 1 nt.

The miR181a agent may increase or decrease the levels of miR181a in thetargeted cell. Where the agent is an inhibitory agent, it inhibits theactivity of the target miRNA by reducing the amount of miR181a RNApresent in the targeted cells, where the target cell may be present invitro or in vivo. By “reducing the amount of” is meant that the level orquantity of the target miRNA in the target cell is reduced by at leastabout 2-fold, usually by at least about 5-fold, e.g., 10-fold, 15-fold,20-fold, 50-fold, 100-fold or more, as compared to a control, i.e., anidentical target cell not treated according to the subject methods.

Where the miR-181a agent increases the activity of the targeted miRNA ina cell, the amount of miR181a is increased in the targeted cells, wherethe target cell may be present in vitro or in vivo. By “increasing theamount of” is meant that the level or quantity of the target miRNA inthe target cell is increased by at least about 2-fold, usually by atleast about 5-fold, e.g., 10-fold, 15-fold, 20-fold, 50-fold, 100-foldor more, as compared to a control, i.e., an identical target cell nottreated according to the subject methods.

By miRNA inhibitory agent is meant an agent that inhibits the activityof the target miRNA. The inhibitory agent may inhibit the activity ofthe target miRNA by a variety of different mechanisms. In certainembodiments, the inhibitory agent is one that binds to the target miRNAand, in doing so, inhibits its activity. Representative miRNA inhibitoryagents include, but are not limited to: antisense oligonucleotides, andthe like. Other agents of interest include, but are not limited to:Naturally occurring or synthetic small molecule compounds of interest,which include numerous chemical classes, though typically they areorganic molecules, preferably small organic compounds having a molecularweight of more than 50 and less than about 2,500 daltons. Candidateagents comprise functional groups necessary for structural interactionwith proteins, particularly hydrogen bonding, and typically include atleast an amine, carbonyl, hydroxyl or carboxyl group, preferably atleast two of the functional chemical groups. The candidate agents oftencomprise cyclical carbon or heterocyclic structures and/or aromatic orpolyaromatic structures substituted with one or more of the abovefunctional groups. Candidate agents are also found among biomoleculesincluding peptides, saccharides, fatty acids, steroids, purines,pyrimidines, derivatives, structural analogs or combinations thereof.Such molecules may be identified, among other ways, by employingappropriate screening protocols.

The antisense reagent may be antisense oligonucleotides (ODN),particularly synthetic ODN having chemical modifications from nativenucleic acids, or nucleic acid constructs that express such antisensemolecules as RNA. The antisense sequence is complementary to thetargeted miRNA, and inhibits its expression. One or a combination ofantisense molecules may be administered, where a combination maycomprise multiple different sequences.

Antisense molecules may be produced by expression of all or a part ofthe target miRNA sequence in an appropriate vector, where thetranscriptional initiation is oriented such that an antisense strand isproduced as an RNA molecule. Alternatively, the antisense molecule is asynthetic oligonucleotide. Antisense oligonucleotides will generally beat least about 7, usually at least about 12, more usually at least about20 nucleotides in length, and not more than about 25, usually not morethan about 23-22 nucleotides in length, where the length is governed byefficiency of inhibition, specificity, including absence ofcross-reactivity, and the like.

Antisense oligonucleotides may be chemically synthesized by methodsknown in the art (see Wagner et al. (1993) supra. and Milligan et al.,supra.) Preferred oligonucleotides are chemically modified from thenative phosphodiester structure, in order to increase theirintracellular stability and binding affinity. A number of suchmodifications have been described in the literature that alter thechemistry of the backbone, sugars or heterocyclic bases.

Among useful changes in the backbone chemistry are phosphorothioates;phosphorodithioates, where both of the non-bridging oxygens aresubstituted with sulfur; phosphoroamidites; alkyl phosphotriesters andboranophosphates. Achiral phosphate derivatives include3′-O′-5′-S-phosphorothioate, 3′-S-5′-O-phosphorothioate,3′-CH2-5′-O-phosphonate and 3′-NH-5′-O-phosphoroamidate. Peptide nucleicacids replace the entire ribose phosphodiester backbone with a peptidelinkage. Sugar modifications are also used to enhance stability andaffinity. The alpha.-anomer of deoxyribose may be used, where the baseis inverted with respect to the natural .beta.-anomer. The 2′-OH of theribose sugar may be altered to form 2′-O-methyl or 2′-O-allyl sugars,which provides resistance to degradation without comprising affinity.Modification of the heterocyclic bases must maintain proper basepairing. Some useful substitutions include deoxyuridine fordeoxythymidine; 5-methyl-2′-deoxycytidine and 5-bromo-2′-deoxycytidinefor deoxycytidine. 5-propynyl-2′-deoxyuridine and5-propynyl-2′-deoxycytidine have been shown to increase affinity andbiological activity when substituted for deoxythymidine anddeoxycytidine, respectively.

Anti-sense molecules of interest include antagomir RNAs, e.g. asdescribed by Krutzfeldt et al., supra., herein specifically incorporatedby reference. Small interfering double-stranded RNAs (siRNAs) engineeredwith certain ‘drug-like’ properties such as chemical modifications forstability and cholesterol conjugation for delivery have been shown toachieve therapeutic silencing of an endogenous gene in vivo. To developa pharmacological approach for silencing miRNAs in vivo, chemicallymodified, cholesterol-conjugated single-stranded RNA analoguescomplementary to miRNAs were developed, termed ‘antagomirs’. AntagomirRNAs may be synthesized using standard solid phase oligonucleotidesynthesis protocols. The RNAs are conjugated to cholesterol, and mayfurther have a phosphorothioate backbone at one or more positions.

Also of interest in certain embodiments are RNAi agents. Inrepresentative embodiments, the RNAi agent targets the precursormolecule of the microRNA, known as pre-microRNA molecule. By RNAi agentis meant an agent that modulates expression of microRNA by a RNAinterference mechanism. The RNAi agents employed in one embodiment ofthe subject invention are small ribonucleic acid molecules (alsoreferred to herein as interfering ribonucleic acids), i.e.,oligoribonucleotides, that are present in duplex structures, e.g., twodistinct oligoribonucleotides hybridized to each other or a singleribooligonucleotide that assumes a small hairpin formation to produce aduplex structure. By oligoribonucleotide is meant a ribonucleic acidthat does not exceed about 100 nt in length, and typically does notexceed about 75 nt length, where the length in certain embodiments isless than about 70 nt. Where the RNA agent is a duplex structure of twodistinct ribonucleic acids hybridized to each other, e.g., an siRNA, thelength of the duplex structure typically ranges from about 15 to 30 bp,usually from about 15 to 29 bp, where lengths between about 20 and 29bps, e.g., 21 bp, 22 bp, are of particular interest in certainembodiments. Where the RNA agent is a duplex structure of a singleribonucleic acid that is present in a hairpin formation, i.e., a shRNA,the length of the hybridized portion of the hairpin is typically thesame as that provided above for the siRNA type of agent or longer by 4-8nucleotides. The weight of the RNAi agents of this embodiment typicallyranges from about 5,000 daltons to about 35,000 daltons, and in manyembodiments is at least about 10,000 daltons and less than about 27,500daltons, often less than about 25,000 daltons.

dsRNA can be prepared according to any of a number of methods that areknown in the art, including in vitro and in vivo methods, as well as bysynthetic chemistry approaches. Examples of such methods include, butare not limited to, the methods described by Sadher et al. (Biochem.Int. 14:1015, 1987); by Bhattacharyya (Nature 343:484, 1990); and byLivache, et al. (U.S. Pat. No. 5,795,715), each of which is incorporatedherein by reference in its entirety. Single-stranded RNA can also beproduced using a combination of enzymatic and organic synthesis or bytotal organic synthesis. The use of synthetic chemical methods enableone to introduce desired modified nucleotides or nucleotide analogs intothe dsRNA. dsRNA can also be prepared in vivo according to a number ofestablished methods (see, e.g., Sambrook, et al. (1989) MolecularCloning: A Laboratory Manual, 2nd ed.; Transcription and Translation (B.D. Hames, and S. J. Higgins, Eds., 1984); DNA Cloning, volumes I and II(D. N. Glover, Ed., 1985); and Oligonucleotide Synthesis (M. J. Gait,Ed., 1984, each of which is incorporated herein by reference in itsentirety).

In certain embodiments, instead of the RNAi agent being an interferingribonucleic acid, e.g., an siRNA or shRNA as described above, the RNAiagent may encode an interfering ribonucleic acid, e.g., an shRNA, asdescribed above. In other words, the RNAi agent may be a transcriptionaltemplate of the interfering ribonucleic acid. In these embodiments, thetranscriptional template is typically a DNA that encodes the interferingribonucleic acid. The DNA may be present in a vector, where a variety ofdifferent vectors are known in the art, e.g., a plasmid vector, a viralvector, etc.

Where it is desirable to increase miR-181a expression in a cell, e.g. toincrease the sensitivity of a T cell to antigen, an agent may bemiR-181a microRNA itself, including any of the modified oligonucleotidesdescribed above with respect to antisense, e.g. cholesterol conjugates,phosphorothioates linkages, and the like. Alternatively, a vector thatexpresses miR-181a, including the pre-miRNA sequence relevant to thetargeted organism.

Expression vectors may be used to introduce the target gene into a cell.Such vectors generally have convenient restriction sites located nearthe promoter sequence to provide for the insertion of nucleic acidsequences. Transcription cassettes may be prepared comprising atranscription initiation region, the target gene or fragment thereof,and a transcriptional termination region. The transcription cassettesmay be introduced into a variety of vectors, e.g. plasmid; retrovirus,e.g. lentivirus; adenovirus; and the like, where the vectors are able totransiently or stably be maintained in the cells, usually for a periodof at least about one day, more usually for a period of at least aboutseveral days to several weeks.

The expression cassette will generally employ an exogenoustranscriptional initiation region, i.e. a promoter other than thepromoter which is associated with the T cell receptor in the normallyoccurring chromosome. The promoter is functional in host cells,particularly host cells targeted by the cassette. The promoter may beintroduced by recombinant methods in vitro, or as the result ofhomologous integration of the sequence by a suitable host cell. Thepromoter is operably linked to the coding sequence of the autoantigen toproduce a translatable mRNA transcript. Expression vectors convenientlywill have restriction sites located near the promoter sequence tofacilitate the insertion of autoantigen sequences.

Expression cassettes are prepared comprising a transcription initiationregion, which may be constitutive or inducible, the gene encoding theautoantigen sequence, and a transcriptional termination region. Theexpression cassettes may be introduced into a variety of vectors.Promoters of interest may be inducible or constitutive, usuallyconstitutive, and will provide for high levels of transcription in thevaccine recipient cells. The promoter may be active only in therecipient cell type, or may be broadly active in many different celltypes. Many strong promoters for mammalian cells are known in the art,including the .beta.-actin promoter, SV40 early and late promoters,immunoglobulin promoter, human cytomegalovirus promoter, retroviralLTRs, etc. The promoters may or may not be associated with enhancers,where the enhancers may be naturally associated with the particularpromoter or associated with a different promoter.

A termination region is provided 3′ to the coding region, where thetermination region may be naturally associated with the variable regiondomain or may be derived from a different source. A wide variety oftermination regions may be employed without adversely affectingexpression.

The various manipulations may be carried out in vitro or may beperformed in an appropriate host, e.g. E. coli. After each manipulation,the resulting construct may be cloned, the vector isolated, and the DNAscreened or sequenced to ensure the correctness of the construct. Thesequence may be screened by restriction analysis, sequencing, or thelike.

As indicated above, the miRNA agent can be introduced into the targetcell(s) using any convenient protocol, where the protocol will varydepending on whether the target cells are in vitro or in vivo. A numberof options can be utilized to deliver the dsRNA into a cell orpopulation of cells such as in a cell culture, tissue, organ or embryo.For instance, RNA can be directly introduced intracellularly. Variousphysical methods are generally utilized in such instances, such asadministration by microinjection (see, e.g., Zernicka-Goetz, et al.(1997) Development 124:1133-1137; and Wianny, et al. (1998) Chromosoma107: 430-439). Other options for cellular delivery includepermeabilizing the cell membrane and electroporation in the presence ofthe dsRNA, liposome-mediated transfection, or transfection usingchemicals such as calcium phosphate. A number of established genetherapy techniques can also be utilized to introduce the dsRNA into acell. By introducing a viral construct within a viral particle, forinstance, one can achieve efficient introduction of an expressionconstruct into the cell and transcription of the RNA encoded by theconstruct.

For example, the inhibitory agent can be fed directly to, injected into,the host organism containing the target gene. The agent may be directlyintroduced into the cell (i.e., intracellularly); or introducedextracellularly into a cavity, interstitial space, into the circulationof an organism, introduced orally, etc. Methods for oral introductioninclude direct mixing of RNA with food of the organism. Physical methodsof introducing nucleic acids include injection directly into the cell orextracellular injection into the organism of an RNA solution. The agentmay be introduced in an amount which allows delivery of at least onecopy per cell. Higher doses (e.g., at least 5, 10, 100, 500 or 1000copies per cell) of the agent may yield more effective inhibition; lowerdoses may also be useful for specific applications.

When liposomes are utilized, substrates that bind to a cell-surfacemembrane protein associated with endocytosis can be attached to theliposome to target the liposome to T cells and to facilitate uptake.Examples of proteins that can be attached include capsid proteins orfragments thereof that bind to T cells, antibodies that specificallybind to cell-surface proteins on T cells that undergo internalization incycling and proteins that target intracellular localizations within Tcells. Gene marking and gene therapy protocols are reviewed by Andersonet al. (1992) Science 256:808-813.

In certain embodiments, a hydrodynamic nucleic acid administrationprotocol is employed. Where the agent is a ribonucleic acid, thehydrodynamic ribonucleic acid administration protocol described indetail below is of particular interest. Where the agent is adeoxyribonucleic acid, the hydrodynamic deoxyribonucleic acidadministration protocols described in Chang et al., J. Virol. (2001)75:3469-3473; Liu et al., Gene Ther. (1999) 6:1258-1266; Wolff et al.,Science (1990) 247: 1465-1468; Zhang et al., Hum. Gene Ther. (1999)10:1735-1737: and Zhang et al., Gene Ther. (1999) 7:1344-1349; are ofinterest.

Additional nucleic acid delivery protocols of interest include, but arenot limited to: those described in U.S. patents of interest include U.S.Pat. Nos. 5,985,847 and 5,922,687 (the disclosures of which are hereinincorporated by reference); WO/11092; Acsadi et al., New Biol. (1991)3:71-81; Hickman et al., Hum. Gen. Ther. (1994) 5:1477-1483; and Wolffet al., Science (1990) 247: 1465-1468; etc.

Depending n the nature of the agent, the active agent(s) may beadministered to the host using any convenient means capable of resultingin the desired modulation of miR-181a in the target cell. Thus, theagent can be incorporated into a variety of formulations for therapeuticadministration. More particularly, the agents of the present inventioncan be formulated into pharmaceutical compositions by combination withappropriate, pharmaceutically acceptable carriers or diluents, and maybe formulated into preparations in solid, semi-solid, liquid or gaseousforms, such as tablets, capsules, powders, granules, ointments,solutions, suppositories, injections, inhalants and aerosols. As such,administration of the agents can be achieved in various ways, includingoral, buccal, rectal, parenteral, intraperitoneal, intradermal,transdermal, intracheal, etc., administration.

The term “unit dosage form,” as used herein, refers to physicallydiscrete units suitable as unitary dosages for human and animalsubjects, each unit containing a predetermined quantity of compounds ofthe present invention calculated in an amount sufficient to produce thedesired effect in association with a pharmaceutically acceptablediluent, carrier or vehicle. The specifications for the novel unitdosage forms of the present invention depend on the particular compoundemployed and the effect to be achieved, and the pharmacodynamicsassociated with each compound in the host.

The pharmaceutically acceptable excipients, such as vehicles, adjuvants,carriers or diluents, are readily available to the public. Moreover,pharmaceutically acceptable auxiliary substances, such as pH adjustingand buffering agents, tonicity adjusting agents, stabilizers, wettingagents and the like, are readily available to the public.

Those of skill in the art will readily appreciate that dose levels canvary as a function of the specific compound, the nature of the deliveryvehicle, and the like. Preferred dosages for a given compound arereadily determinable by those of skill in the art by a variety of means.

Introduction of an effective amount of an miR-181a agent into amammalian cell as described above results in a modulation of targetgene(s) expression, resulting in a modification of the T cell signalingthreshold and sensitivity to antigen.

The above described methods work in any mammalian cell, whererepresentative mammal cells of interest include, but are not limited tocells of: ungulates or hooved animals, e.g., cattle, goats, pigs, sheep,etc.; rodents, e.g., hamsters, mice, rats, etc.; lagomorphs, e.g.,rabbits; primates, e.g., monkeys, baboons, humans, etc.; and the like.

Before, during, or after treatment, the host may be assessed for immuneresponsiveness to a candidate antigen by various methods known in theart. The diagnosis may determine the level of reactivity, e.g. based onthe number of reactive T cells found in a sample, as compared to anegative control from a naive host, or standardized to a data curveobtained from one or more patients. In addition to detecting thequalitative and quantitative presence of reactive T cells, the T cellsmay be typed as to the expression of cytokines known to increase orsuppress inflammatory responses. It may also be desirable to type theepitopic specificity of the reactive T cells.

T cells may be isolated from patient peripheral blood, lymph nodes, orpreferably from the site inflammation. Reactivity assays may beperformed on primary T cells, or the cells may be fused to generatehybridomas. Such reactive T cells may also be used for further analysisof disease progression, by monitoring their in situ location, T cellreceptor utilization, etc. Assays for monitoring T cell responsivenessare known in the art, and include proliferation assays and cytokinerelease assays.

Proliferation assays measure the level of T cell proliferation inresponse to a specific antigen, and are widely used in the art. In anexemplary assay, patient lymph node, blood or spleen cells are obtained.A suspension of from about 10⁴ to 10⁷ cells, usually from about 10⁵ to10⁶ cells is prepared and washed, then cultured in the presence of acontrol antigen, and test antigens. The test antigens may be anypeptides of interest. The cells are usually cultured for several days.Antigen-induced proliferation is assessed by the monitoring thesynthesis of DNA by the cultures, e.g. incorporation of ³H-thymidineduring the last 18 H of culture.

Enzyme linked immunosorbent assay (ELISA) assays are used to determinethe cytokine profile of reactive T cells, and may be used to monitor forthe expression of such cytokines as IL-2, IL-4, IL-5, γIFN, etc. Thecapture antibodies may be any antibody specific for a cytokine ofinterest, where supernatants from the T cell proliferation assays, asdescribed above, are conveniently used as a source of antigen. Afterblocking and washing, labeled detector antibodies are added, and theconcentrations of protein present determined as a function of the labelthat is bound.

The peptides may be defined by screening with a panel of peptidesderived from the test protein. The peptides will have at least about 8and not more than about 30 amino acids, more usually not more than about20 amino acids in length. A panel of peptides may represent the lengthof a protein sequence, i.e. all residues are present in at least onepeptide.

Where the miR-181a agent is acting to decrease expression of miR-181a,the net effect is to increase the threshold for antigen signaling, andto decrease the sensitivity of a T cell to antigen. The effect may bemediated in mature T cells, e.g. non-naïve T cells that have beenexposed to an antigen of interest. Alternatively the target cell may bea progenitor to such mature T cells. Conditions of interest fordownregulating T cells responses include allergic responses, autoimmunediseases, and in conjunction with transplantation, where graft rejectionmay occur as a result of T cell mediated immune responses.

Immune related diseases include: autoimmune diseases in which the immuneresponse aberrantly attacks self-antigens, examples of which include butare not limited to multiple sclerosis (MS), acute disseminatedencephalomyelitis (ADEM), rheumatoid arthritis (RA), type I autoimmunediabetes (IDDM), atherosclerosis, systemic lupus erythematosus (SLE),anti-phospholipid antibody syndrome, Guillain-Barre syndrome (GBS) andits subtypes acute inflammatory demyelinating polyradiculoneuropathy,and the autoimmune peripheral neuropathies; allergic diseases in whichthe immune system aberrantly attacks molecules such as pollen, dust miteantigens, bee venom, peanut oil and other foods, etc.; and tissuetransplant rejection in which the immune system aberrantly attacksantigens expressed or contained within a grafted or transplanted tissue,such as blood, bone marrow cells, or solid organs including hearts,lungs, kidneys and livers; and the immune response against tumors.Samples are obtained from patients with clinical symptoms suggestive ofan immune-related disease or with an increased likelihood for developingsuch a disease based on family history or genetic testing.

Other immune related diseases include allergy, or hypersensitivity, ofthe immune system, including delayed type hypersensitivity and asthma.Most cases of “atopic” or “allergic” asthma occur in subjects whom alsoexhibit immediate hypersensitivity responses to defined environmentalallergens, and challenge of the airways of these subjects with suchallergens can produce reversible airway obstruction. Both T cells andmast cells (and other FcRI+ cells) can have effector cell andimmunoregulatory roles in these disorders.

NKT cells constitute a lymphocyte subpopulation that are abundant in thethymus, spleen, liver and bone marrow and are also present in the lung.They develop in the thymus from the CD4⁺CD8⁺ progenitor cells andcirculate in the blood, have distinctive cytoplasmic granules, and canbe functionally identified by their ability to kill certain lymphoidtumor cell lines in vitro without the need for prior immunization oractivation. The mechanism of NKT cell killing is the same as that usedby the cytotoxic T cells generated in an adaptive immune response;cytotoxic granules are released onto the surface of the bound targetcell, and the effector proteins they contain penetrate the cell membraneand induce programmed cell death. There is evidence that suggests NKTcells are involved in the pathogenesis of conditions including asthmaand certain autoimmune diseases.

Where a patient is undergoing transplantation, it may be desirable todown-regulate generally or specifically the patient immune response. Insuch cases, the therapeutic miR-181a agent may be introduced prior to,concurrently with, or following the transplantation.

Where the miR-181a agent is acting to increase expression of miR-181a,the net effect is to decrease the threshold for signaling, and toincrease the sensitivity of a T cell to antigen. Conditions of interestfor upregulating T cell responsiveness include conditions where there isan inadequate immune response, e.g. in the induction of immuneresponsiveness to cancer, to chronically infected cells, and the like.

Upregulation of miR-181a finds use in eliciting an immune response in anautologous, allogeneic or xenogeneic host. For example, where a tumorcell or a chronically infected cell expresses a protein, orover-expresses the protein relative to normal cells, a cytolytic immuneresponse may be induced, where the tumor cell or infected cell ispreferentially killed. The antigen for such purposes may be from thesame or a different species. As used herein, the term antigen isintended to refer to a molecule capable of eliciting an immune responsein a mammalian host, which may be a humoral immune response, i.e.characterized by the production of antigen-specific antibodies, or acytotoxic immune response, i.e. characterized by the production ofantigen specific cytotoxic T lymphocytes. The miR-181a agent isadministered in combination with the tumor antigen.

Several methods exist which can be used to induce an immune responseagainst weakly antigenic protein, i.e. autologous proteins, etc. Theimmunogen is usually delivered in vivo to elicit a response, but in somecases it is advantageous to prime antigen presenting cells, e.g.dendritic cells, ex vivo prior to introducing them into the host animal.

In one embodiment, polypeptide antigens are mixed with an adjuvant thatwill augment specific immune responses to the antigen, wherein theadjuvant comprises an agent that upregulated miR-181a in the targetedcell. Vaccine antigens may be presented using microspheres, liposomes,may be produced using an immunostimulating complex (ISCOM), as is knownin the art.

Diagnostic and Prognostic Methods

In another embodiment of the invention, the detection of changes inmiR-181a sequence, including changes in the promoter region, and thelike, or expression of miR-181a is used as a marker in diagnostic orprognostic evaluation of a patient for conditions associated with T cellfunction, which conditions include, without limitation, a predispositionto autoimmune disease, a predisposition to T cell mediatedimmunodeficiency, a predisposition to atopy, and the like. Diagnosticmethods include detection of specific markers correlated with specificstages in the pathological processes leading to conditions associatedwith T cell mediated immune dysfunction.

In general, such methods involve detecting altered levels or activity ofmiR-181a in the cells or tissue of an individual or a sample therefrom.A variety of different assays can be utilized to detect changes inexpression, including both methods that detect the microRNA, theunprocessed transcripts, and evaluation of genomic sequences. Morespecifically, the diagnostic and prognostic methods disclosed hereininvolve obtaining a sample from an individual and determiningqualitatively or quantitatively, the activity of miR-181a in the sample.Usually this determined value or test value is compared against sometype of reference or baseline value. For example, a sequence thatdiffers from the wild-type miR-181a sequence is a marker, as is alteredexpression levels relative to the wild-type.

Nucleic acids that are specific for the sequence of miR-181a are used toscreen patient samples for altered activity of the microRNA, or for thepresence of altered DNA in the cell. Samples can be obtained from avariety of sources. For example, since the methods are designedprimarily to diagnosis and assess risk factors for humans to T cellmediated immune disorders, samples are typically obtained from a humansubject. However, the methods can also be utilized with samples obtainedfrom various other mammals, such as primates, e.g. apes and chimpanzees,mice, cats, rats, and other animals. Such samples are referred to as apatient sample.

Samples can be obtained from the tissues or fluids of an individual, aswell as from cell cultures or tissue homogenates. For example, samplescan be obtained from peripheral blood, serum, semen, saliva, tears,urine, fecal material, etc., preferably a hematopoietic cell sample.Also included in the term are derivatives and fractions of such cellsand fluids. Samples can also be derived from in vitro cell cultures,including the growth medium, recombinant cells and cell components. Thenumber of cells in a sample will often be at least about 10², usually atleast 10³, and may be about 10⁴ or more. The cells may be dissociated,in the case of solid tissues, or tissue sections may be analyzed.Alternatively a lysate of the cells may be prepared.

The various test values determined for a sample from an individualbelieved to have an immune dysfunction are typically are comparedagainst a baseline value to assess the extent of altered activity orexpression, if any. This baseline value can be any of a number ofdifferent values. In some instances, the baseline value is a valueestablished in a trial using a healthy cell or tissue sample that is runin parallel with the test sample. Alternatively, the baseline value canbe a statistical value (e.g., a mean or average) established from apopulation of control cells or individuals. For example, the baselinevalue can be a value or range which is characteristic of a controlindividual or control population. For instance, the baseline value canbe a statistical value or range that is reflective of expression levelsfor the general population, or more specifically, healthy individualsnot susceptible to T cell mediated immune dysfunction.

Some of the diagnostic and prognostic methods that involve the detectionof miR-181a begin with the lysis of cells and subsequent purification ofnucleic acids from other cellular material, particularly RNAtranscripts. A nucleic acid derived from an RNA transcript refers to anucleic acid for whose synthesis the RNA transcript, or a subsequencethereof, has ultimately served as a template. Thus, a cDNA reversetranscribed from an RNA, an RNA transcribed from that cDNA, a DNAamplified from the cDNA, an RNA transcribed from the amplified DNA, areall derived from the RNA transcript and detection of such derivedproducts is indicative of the presence and/or abundance of the originaltranscript in a sample. Thus, suitable samples include, but are notlimited to, RNA transcripts, cDNA reverse transcribed from the RNA, cRNAtranscribed from the cDNA, DNA amplified from nucleic acids, and RNAtranscribed from amplified DNA.

A number of methods are available for analyzing nucleic acids for thepresence of a specific sequence, e.g. upregulated expression. Thenucleic acid may be amplified by conventional techniques, such as thepolymerase chain reaction (PCR), to provide sufficient amounts foranalysis. The use of the polymerase chain reaction is described in Saikiet al. (1985) Science 239:487, and a review of techniques may be foundin Sambrook, et al. Molecular Cloning: A Laboratory Manual, CSH Press1989, pp. 14.2-14.33.

A detectable label may be included in an amplification reaction.Suitable labels include fluorochromes, e.g. fluorescein isothiocyanate(FITC), rhodamine, Texas Red, phycoerythrin, allophycocyan in,6-carboxyfluorescein (6-FAM),2,7-dimethoxy-4,5-dichloro-6-carboxyfluorescein (JOE),6-carboxy-X-rhodamine (ROX), 6-carboxy-2,4,7,4,7-hexachlorofluorescein(HEX), 5-carboxyfluorescein (5-FAM) orN,N,N,N-tetramethyl-6-carboxyrhodamine (TAMRA), radioactive labels, e.g.³²P, ³⁵S, ³H; etc. The label may be a two stage system, where theamplified DNA is conjugated to biotin, haptens, etc. having a highaffinity binding partner, e.g. avidin, specific antibodies, etc., wherethe binding partner is conjugated to a detectable label. The label maybe conjugated to one or both of the primers. Alternatively, the pool ofnucleotides used in the amplification is labeled, so as to incorporatethe label into the amplification product.

The sample nucleic acid, e.g. amplified, labeled, cloned fragment, etc.is analyzed by one of a number of methods known in the art. Probes maybe hybridized to northern or dot blots, or liquid hybridizationreactions performed. The nucleic acid may be sequenced by dideoxy orother methods, and the sequence of bases compared to a wild-typesequence. Single strand conformational polymorphism (SSCP) analysis,denaturing gradient gel electrophoresis (DGGE), and heteroduplexanalysis in gel matrices are used to detect conformational changescreated by DNA sequence variation as alterations in electrophoreticmobility. Fractionation is performed by gel or capillaryelectrophoresis, particularly acrylamide or agarose gels.

In situ hybridization methods are hybridization methods in which thecells are not lysed prior to hybridization. Because the method isperformed in situ, it has the advantage that it is not necessary toprepare RNA from the cells. The method usually involves initially fixingtest cells to a support (e.g., the walls of a microtiter well) and thenpermeabilizing the cells with an appropriate permeabilizing solution. Asolution containing labeled probes for an ischemia associated gene orischemia pathway gene is then contacted with the cells and the probesallowed to hybridize with neuroprotective gene nucleic acids. Excessprobe is digested, washed away and the amount of hybridized probemeasured. This approach is described in greater detail by Harris, D. W.(1996) Anal. Biochem. 243:249-256; Singer, et al. (1986) Biotechniques4:230-250; Haase et al. (1984) Methods in Virology, vol. VII, pp.189-226; and Nucleic Acid Hybridization: A Practical Approach (Hames, etal., eds., 1987).

A variety of so-called “real time amplification” methods or “real timequantitative PCR” methods can also be utilized to determine the quantityof ischemia associated gene or ischemia pathway gene mRNA present in asample. Such methods involve measuring the amount of amplificationproduct formed during an amplification process. Fluorogenic nucleaseassays are one specific example of a real time quantitation method thatcan be used to detect and quantitate miR-181a. In general such assayscontinuously measure PCR product accumulation using a dual-labeledfluorogenic oligonucleotide probe—an approach frequently referred to inthe literature simply as the “TaqMan” method.

The probe used in such assays is typically a short (ca. 20-25 bases)polynucleotide that is labeled with two different fluorescent dyes. The5′ terminus of the probe is typically attached to a reporter dye and the3′ terminus is attached to a quenching dye, although the dyes can beattached at other locations on the probe as well. For measuringmiR-181a, the probe is designed to have at least substantial sequencecomplementarity with a probe binding site on the miR-181a transcript.Upstream and downstream PCR primers that bind to regions that flank themiR-181a gene may also added to the reaction mixture. Probes may also bemade by in vitro transcription methods.

When the probe is intact, energy transfer between the two fluorophorsoccurs and the quencher quenches emission from the reporter. During theextension phase of PCR, the probe is cleaved by the 5′ nuclease activityof a nucleic acid polymerase such as Taq polymerase, thereby releasingthe reporter dye from the polynucleotide-quencher complex and resultingin an increase of reporter emission intensity that can be measured by anappropriate detection system.

Compound Screening

Compound screening may be performed using an in vitro model, agenetically altered cell or animal, purified microRNA, purified proteincorresponding to polypeptides demonstrated herein to be regulated bymiR-181a, and the like. One can identify ligands or substrates that bindto, modulate, inhibit, potentiate, or mimic the action of the microRNA.Assays may include functional analysis of T cell function, e.g. asprovided in the Examples, where calcium uptake, cytokine production,etc. is monitored in a T cell in the absence or presence of a candidateagent. Other assays include analysis of expression of proteinsidentified herein as being regulated by miR-181a. Assays may alsoinclude analysis of the specific phosphatase proteins for enzymaticactivity, to the effect of the microRNA on phosphatase expression, etc.

In one embodiment, compound screening is performed to determine theactivity of a candidate agent with respect to dampening the activity ofmultiple negative regulators in the T cell receptor (TCR) signalingpathway, including PTPN22 (PTP-PEST) and the dual specificityphosphatases DUSP5 and DUSP6 (PYST1). In such a screening assay, forexample, a candidate agent may be tested for coordinate down-regulationof the activity of PTPN22, DUSP5 and DUSP6. Such an agent may be testedby contacting the purified proteins with a candidate agent, e.g. aphosphatase inhibitor with specificity broad enough to inhibit at leastpartially each of these enzymes, and testing the activity of thephosphatase in a suitable assay, e.g. against known substrates. Forexample, see Kovanen et al. (2003) J Biol. Chem. 278(7):5205-13; Dowd etal. (1998) J Cell Sci. 111 (Pt 22):3389-99; Matthews et al. (1992) MolCell Biol. 12(5):2396-405, each herein specifically incorporated byreference for teachings of assays relevant to the specific phosphatases.Alternatively, a cell may be contacted with a candidate agent forregulation of transcription or translation of each of these enzymes. Insuch assays, the miR-181a may serve as a positive control forcoordinately regulating expression of these proteins.

The microRNA or phosphatase polypeptides include those that, by virtueof the degeneracy of the genetic code, are not identical in sequence tothe disclosed nucleic acids, and variants thereof. Variant sequences caninclude amino acid (aa) or nucleotide substitutions, additions ordeletions. The substitutions can be conservative amino acidsubstitutions or substitutions to eliminate non-essential amino acids,such as to alter a glycosylation site, a phosphorylation site or anacetylation site, or to minimize misfolding by substitution or deletionof one or more cysteine residues that are not necessary for function.Variants can be designed so as to retain or have enhanced biologicalactivity of a particular region of the protein (e.g., a functionaldomain and/or, where the polypeptide is a member of a protein family, aregion associated with a consensus sequence). Variants also includefragments of the polypeptides disclosed herein, particularlybiologically active fragments and/or fragments corresponding tofunctional domains. Fragments of interest will typically be at leastabout 10 to at least about 15 residues in length, usually at least about50 residues in length, and can be as long as 300 residues in length orlonger, but will usually not exceed about 500 residues in length.

Transgenic animals or cells derived therefrom are also used in compoundscreening. Transgenic animals may be made through homologousrecombination, where the normal locus corresponding to a geneticsequence identified herein is altered. Alternatively, a nucleic acidconstruct is randomly integrated into the genome. Vectors for stableintegration include plasmids, retroviruses and other animal viruses,YACs, and the like. A series of small deletions and/or substitutions maybe made in the coding sequence to determine the role of different exonsin kinase activity, oncogenesis, signal transduction, etc. Of interestis the use of miR-181a to construct transgenic animal models for immunedysfunction, where expression of the regulated polypeptides in the Tcell signaling pathway are altered. Specific constructs of interestinclude antisense sequences that block expression of the targeted geneand expression of dominant negative mutations. A detectable marker, suchas lac Z may be introduced into the locus of interest, whereup-regulation of expression will result in an easily detected change inphenotype. One may also provide for expression of the target gene orvariants thereof in cells or tissues where it is not normally expressedor at abnormal times of development. By providing expression of thetarget protein in cells in which it is not normally produced, one caninduce changes in cell behavior.

Compound screening identifies agents that coordinately modulate activityof the miR-181a regulated polypeptides. Of particular interest arescreening assays for agents that have a low toxicity for human cells. Awide variety of assays may be used for this purpose, including labeledin vitro protein-protein binding assays, electrophoretic mobility shiftassays, immunoassays for protein binding, and the like. Knowledge of the3-dimensional structure of the encoded protein, derived fromcrystallization of purified recombinant protein, could lead to therational design of small drugs that specifically inhibit activity. Thesedrugs may be directed at specific domains.

The term “agent” as used herein describes any molecule, e.g. protein orpharmaceutical, with the capability of altering or mimicking thephysiological function of a ischemia associated kinase corresponding toIschemia associated genes. Generally a plurality of assay mixtures arerun in parallel with different agent concentrations to obtain adifferential response to the various concentrations. Typically one ofthese concentrations serves as a negative control, i.e. at zeroconcentration or below the level of detection.

Candidate agents encompass numerous chemical classes, though typicallythey are organic molecules, preferably small organic compounds having amolecular weight of more than 50 and less than about 2,500 daltons.Candidate agents comprise functional groups necessary for structuralinteraction with proteins, particularly hydrogen bonding, and typicallyinclude at least an amine, carbonyl, hydroxyl or carboxyl group,preferably at least two of the functional chemical groups. The candidateagents often comprise cyclical carbon or heterocyclic structures and/oraromatic or polyaromatic structures substituted with one or more of theabove functional groups. Candidate agents are also found amongbiomolecules including peptides, saccharides, fatty acids, steroids,purines, pyrimidines, derivatives, structural analogs or combinationsthereof.

Candidate agents are obtained from a wide variety of sources includinglibraries of synthetic or natural compounds. For example, numerous meansare available for random and directed synthesis of a wide variety oforganic compounds and biomolecules, including expression of randomizedoligonucleotides and oligopeptides. Alternatively, libraries of naturalcompounds in the form of bacterial, fungal, plant and animal extractsare available or readily produced. Additionally, natural orsynthetically produced libraries and compounds are readily modifiedthrough conventional chemical, physical and biochemical means, and maybe used to produce combinatorial libraries. Known pharmacological agentsmay be subjected to directed or random chemical modifications, such asacylation, alkylation, esterification, amidification, etc. to producestructural analogs. Test agents can be obtained from libraries, such asnatural product libraries or combinatorial libraries, for example. Anumber of different types of combinatorial libraries and methods forpreparing such libraries have been described, including for example, PCTpublications WO 93/06121, WO 95/12608, WO 95/35503, WO 94/08051 and WO95/30642, each of which is incorporated herein by reference.

Where the screening assay is a binding assay, one or more of themolecules may be joined to a label, where the label can directly orindirectly provide a detectable signal. Various labels includeradioisotopes, fluorescers, chemiluminescers, enzymes, specific bindingmolecules, particles, e.g. magnetic particles, and the like. Specificbinding molecules include pairs, such as biotin and streptavidin,digoxin and antidigoxin, etc. For the specific binding members, thecomplementary member would normally be labeled with a molecule thatprovides for detection, in accordance with known procedures.

A variety of other reagents may be included in the screening assay.These include reagents like salts, neutral proteins, e.g. albumin,detergents, etc that are used to facilitate optimal protein-proteinbinding and/or reduce non-specific or background interactions. Reagentsthat improve the efficiency of the assay, such as protease inhibitors,nuclease inhibitors, anti-microbial agents, etc. may be used. Themixture of components are added in any order that provides for therequisite binding. Incubations are performed at any suitabletemperature, typically between 4 and 40° C. Incubation periods areselected for optimum activity, but may also be optimized to facilitaterapid high-throughput screening. Typically between 0.1 and 1 hours willbe sufficient.

Preliminary screens can be conducted by screening for compounds capableof binding to polypeptides in the TCR signaling pathway, e.g. PTN22,DUSP5 and DUSP6, as at least some of the compounds so identified arelikely modulators of the activity of these proteins. The binding assaysusually involve contacting a protein with one or more test compounds andallowing sufficient time for the protein and test compounds to form abinding complex. Any binding complexes formed can be detected using anyof a number of established analytical techniques. Protein binding assaysinclude, but are not limited to, methods that measure co-precipitation,co-migration on non-denaturing SDS-polyacrylamide gels, and co-migrationon Western blots (see, e.g., Bennet, J. P. and Yamamura, H. I. (1985)“Neurotransmitter, Hormone or Drug Receptor Binding Methods,” inNeurotransmitter Receptor Binding (Yamamura, H. I., et al., eds.), pp.61-89. The proteins utilized in such assays can be naturally expressed,cloned or synthesized.

Certain screening methods involve screening for a compound thatmodulates the expression of polypeptides in the TCR signaling pathway,e.g. PTN22, DUSP5 and DUSP6, usually coordinately modulates expression.Such methods generally involve conducting cell-based assays in whichtest compounds are contacted with one or more cells expressingpolypeptides in the TCR signaling pathway, e.g. PTN22, DUSP5 and DUSP6and then detecting and an increase in polypeptides in the TCR signalingpathway. Some assays are performed with cells of the immune system, e.g.T cells.

Expression can be detected in a number of different ways. The expressionlevel of a gene in a cell can be determined by probing the mRNAexpressed in a cell with a probe that specifically hybridizes with atranscript (or complementary nucleic acid derived therefrom) of thegene. Probing can be conducted by lysing the cells and conductingNorthern blots or without lysing the cells using in situ-hybridizationtechniques. Alternatively, a protein can be detected using immunologicalmethods in which a cell lysate is probe with antibodies thatspecifically bind to the protein.

Other cell-based assays are reporter assays. Certain of these assays areconducted with a heterologous nucleic acid construct that includes apromoter that is operably linked to a reporter gene that encodes adetectable product. A number of different reporter genes can beutilized. Some reporters are inherently detectable. An example of such areporter is green fluorescent protein that emits fluorescence that canbe detected with a fluorescence detector. Other reporters generate adetectable product. Often such reporters are enzymes. Exemplary enzymereporters include, but are not limited to, β-glucuronidase, CAT(chloramphenicol acetyl transferase; Alton and Vapnek (1979) Nature282:864-869), luciferase, β-galactosidase and alkaline phosphatase (Toh,et al. (1980) Eur. J. Biochem. 182:231-238; and Hall et al. (1983) J.Mol. Appl. Gen. 2:101).

In these assays, cells harboring the reporter construct are contactedwith a test compound. A test compound that either activates the promoterby binding to it or triggers a cascade that produces a molecule thatactivates the promoter causes expression of the detectable reporter.Certain other reporter assays are conducted with cells that harbor aheterologous construct that includes a transcriptional control elementthat activates expression. Here, too, an agent that binds to thetranscriptional control element to activate expression of the reporteror that triggers the formation of an agent that binds to thetranscriptional control element to activate reporter expression, can beidentified by the generation of signal associated with reporterexpression.

The level of expression or activity can be compared to a baseline value.As indicated above, the baseline value can be a value for a controlsample or a statistical value that is representative of a controlpopulation (e.g., healthy individuals). Expression levels can also bedetermined for cells that do not express one of the signaling pathwaygenes as a negative control. Such cells generally are otherwisesubstantially genetically the same as the test cells.

A variety of different types of cells can be utilized in the reporterassays. Certain cells are T cells. Other eukaryotic cells can be any ofthe cells typically utilized in generating cells that harbor recombinantnucleic acid constructs. Exemplary eukaryotic cells include, but are notlimited to, yeast, and various higher eukaryotic cells such as the COS,CHO and HeLa cell lines.

Various controls can be conducted to ensure that an observed activity isauthentic including running parallel reactions with cells that lack thereporter construct or by not contacting a cell harboring the reporterconstruct with test compound. Compounds can also be further validated asdescribed below.

Compounds that are initially identified by any of the foregoingscreening methods can be further tested to validate the apparentactivity. The basic format of such methods involves administering a leadcompound identified during an initial screen to an animal that serves asa model for humans and then determining if the T cell signaling pathwayhas been altered. The animal models utilized in validation studiesgenerally are mammals. Specific examples of suitable animals include,but are not limited to, primates, mice, and rats.

Certain methods are designed to test not only the ability of a leadcompound to alter activity in an animal model, but to provide protectionagainst immune dysfunction. In such methods, a lead compound isadministered to the model animal (i.e., an animal, typically a mammal,other than a human). The animal is subsequently subjected to an immunechallenge, e.g. immunization with an autoantigen, allergic challenge,etc. Compounds able to achieve the desired effect are good candidatesfor further study.

Active test agents identified by the screening methods described hereincan serve as lead compounds for the synthesis of analog compounds.Typically, the analog compounds are synthesized to have an electronicconfiguration and a molecular conformation similar to that of the leadcompound. Identification of analog compounds can be performed throughuse of techniques such as self-consistent field (SCF) analysis,configuration interaction (CI) analysis, and normal mode dynamicsanalysis. Computer programs for implementing these techniques areavailable. See, e.g., Rein et al., (1989) Computer-Assisted Modeling ofReceptor-Ligand Interactions (Alan Liss, New York).

EXPERIMENTAL Example 1

T cell sensitivity to antigen is intrinsically regulated duringmaturation to ensure proper development of tolerance and immunity, butthe molecules that govern this refinement remain elusive. Here we showthat miR-181a, a member of an abundant class of ˜22 nucleotideendogenous small regulatory RNAs, can quantitatively modulate T cellsensitivity to antigens by controlling the expression of multiple targetgenes. Increasing miR-181a expression in mature T cells causes a markedincrease in T cell activation and augments T cell sensitivity to peptideantigens. Moreover, T cell blasts with higher miR-181a expression becomereactive to antagonists—the inhibitory peptide antigens that arenormally incapable of T cell activation alone but can block agonistligand stimulation. These effects are in part achieved by reducing theexpression of multiple negative regulators in the T cell receptor (TCR)signaling pathway, including PTPN22 and the dual specificityphosphatases DUSP5 and DUSP6. This results in an increase in the steadystate levels of phosphorylated intermediates in the TCR signalingpathway and a reduction in the TCR signaling threshold, thusquantitatively and qualitatively enhancing T cell sensitivity toantigens. Consistent with the observation that higher miR-181aexpression correlates with greater T cell sensitivity in immature Tcells, inhibiting miR-181a expression by a specific “antagomir” reducesthe sensitivity to antigens in naïve T cells and affects positive andnegative selection in thymocytes. Thus miR-181a acts as a ‘rheostat’that tunes T cell sensitivity at various stages of T cell development.

One of the key features of a functioning immune system is its ability todistinguish antigens of foreign origin from those derived endogenouslyand to mount an immune response against the former. With respect to Tcells, this goal is achieved through antigen recognition by T cellreceptors (TCRs) and a highly ordered developmental process in thethymus and in secondary lymphoid organs. TCRs constantly sample adiverse set of self and foreign peptide antigens presented in majorhistocompatibility complexes (MHCs) on the surface of antigen presentingcells (APCs) and these interactions elicit discrete intracellularsignals and T cell responses. The mature T cell's response to antigen islargely dictated by the binding characteristics of its TCR for a givenpeptide-MHC complex (pMHC). In general, pMHC ligands with slowerdissociation rates produce stronger TCR signals and lead to higher Tcell reactivity to the antigenic peptides. Even in cases where there isnot an apparent correlation with dissociation rate in solution, recenttheoretical work suggests that this may well reflect the stability ofTCR:pMHC complex in the context of cell-cell interactions.

Variations in the antigenic peptide affinities to TCRs may lead to bothquantitative and qualitative changes in its ability to activate TCRsignaling pathways and T cell responses. Typically, the most stable pMHCcomplexes with respect to TCR binding are agonists, while the lessstable variants are weak agonists and then antagonists, which are notable to activate T cells more than partially themselves and also blockresponses to agonist ligand. Although a number of models have beenproposed to explain the kinetic discrimination in T cell activation,exactly how T cells sense quantitative changes in antigenic peptideaffinities through their TCRs and produce both quantitatively andqualitatively different responses remains an intensive area of study.

In addition, T cell responsiveness and TCR signaling to a specificligand also vary with different developmental stages, suggesting that Tcell sensitivity to antigens is intrinsically regulated duringdevelopment. For example, in immature CD4+CD8+ double positivethymocytes, low affinity antigenic peptides that are unable to activatemature effector T cells are sufficient to induce strong activation andclonal deletion; antagonists that are normally inhibitory to effector Tcells can induce positive selection. These observations demonstrate thatT cell sensitivity is intrinsically regulated to ensure the properdevelopment of specificity and sensitivity to foreign antigens whileavoiding self-recognition. However, little is known about how intrinsicmolecular programs influence T cell sensitivity toward antigens.

Recent studies suggest that miRNA-mediated gene regulation may representa fundamental layer of posttranscriptional genetic programs in metazoangenomes and have broad effects on gene expression. MiRNA genes are anintegral component of animal genomes and are dynamically regulatedduring development. These ˜22-nt RNAs can repress the expression ofprotein-coding genes by targeting cognate messenger RNAs for degradationor translational repression. The cellular protein machineries involvedin miRNA processing and function were also shown to play importantfunctional roles, for example in the development of limbs and T cells inmice.

Furthermore, many miRNAs are differentially regulated in hematopoieticlineages and some have been shown to play roles in controlling thedevelopment of immune cells. The mechanisms by which miRNAs exert theseeffects are unclear, as is whether they have any specific role in theadaptive immune response.

Dynamic Regulation of miR-181a Expression During T Cell Development.

Among many known hematopoietic miRNAs, miR-181a is preferentiallyexpressed in the B cell but not T cell lineages in the mouse bonemarrow. Ectopic expression of miR-181a in hematopoietic stem/progenitorcells results in a marked increase in B cell differentiation, whileaccompanied by a decrease in the percentage of T lymphocytes in theperipheral blood of transplanted mice. Interestingly, miR-181a is alsostrongly expressed in the mouse thymus, which consists mainly of Tcells, suggesting that miR-181a may play some role in the developmentand function of T cells.

We examined how miR-181a expression is regulated during T celldevelopment and maturation. T cell differentiation in the thymus can bedivided into discrete stages characterized by the expression of CD4 andCD8 coreceptors. CD4 and CD8 double-negative (DN) cells, which are theearly T cell progenitors in the thymus, can differentiate into CD4 andCD8 double positive cells (DP), and then further differentiate intomature CD4 or CD8 single-positive (SP) cells. DN cells can be furtherfractionated based on the expression of CD44 and CD25 into DN1 (CD44₊CD25⁻), DN2 (CD44₊ CD25₊), DN3 (CD44⁻ CD25₊), and DN4 (CD44⁻ CD25⁻) cellpopulations, in the order of their appearance during development. Wepurified these thymic T cell populations by FACS sorting according tosurface marker expression. We also obtained CD4₊ naïve T cells from thelymph nodes of Rag2−/−5C.C7-αβ TCR transgenic mice and derived Th1 andTh2 effector cells.

Further analysis of miR-181a expression in these immature and mature Tcell populations using a quantitative real-time PCR assay revealed avery dynamic regulation of miR-181a expression during T cell maturation(FIG. 1A). MiR-181a expression is high in the early T celldifferentiation stages in thymus, and its expression is significantlyup-regulated from ˜427 to ˜858 to ˜1077 copies/cell in the DN1-3 cellpopulations, respectively. MiR-181a expression then decreases in thelater stages. Its expression drops sharply to ˜225, 141, 42, 14copies/cell in DN4, DP, CD4 SP, and CD8 SP thymocytes, respectively.Similarly, we noticed a further decrease of miR-181a expression to ˜29copies/cell in naïve cells, but only 12 and ˜8 copies/cell in the blastsof Th1 and Th2 cells, respectively (FIG. 1A). The results section tillthis point are duplicate of para 00145 to 00147. Do we let it be presentin duplicate as it is relevant to the rest of the example here? Notably,when comparing to the mature Th1 and Th2 effector cells, miR-181aexpression levels seem to be relatively higher in DP populations—the Tcell populations that are more sensitive to pMHCs with low orintermediate affinities.

In comparison, miR-142-3p, a hematopoietic-specific miRNA, has distinctexpression patterns during T cell development and maturation (FIG. 25).The dynamic regulation of miR-181a expression in various T cellpopulations indicates that miR-181a plays a role in T cell maturationand functional differentiation (FIG. 1A). Indeed, using a OP9-DL1(delta-like-1) stromal and thymocyte coculture assay, we have shown thatectopic expression of miR-181a in DN thymic progenitor cells cause aquantitative increase in the percentage of DP cells and a decrease inthe CD8₊ cells, suggesting that miR-181a can influence the developmentof thymic progenitor cells during both pre-TCR and TCR dependent stages.

MiR-181a Augments TCR Signaling Strength.

To investigate miR-181a's role, if any, in antigen recognition by matureT cells, we assessed the effect of its expression on TCR signaling inCD4⁺ T cell blasts. We increased the expression of miR-181a in primed Tcell blasts derived from 5C.C7 TCR transgenic mice by retroviraltransduction. Ectopic expression resulted in an approximately three tofive-fold increase in miR-181a levels in the mature T cell blasts. Tcells were then stimulated with CH27 antigen presenting cells (APCs)pre-loaded with a non-saturating amount of agonist peptide derived fromMoth Cytochrome C (MCC a.a.88-103), and then TCR signaling strength wasdetermined by measuring calcium elevation using video microscopy andratio imaging.

Elevated miR-181a expression in T cell blasts resulted in a substantialincrease in intracellular calcium upon stimulation by the MCC peptideantigen, whereas a mutant miR-181a with alterations in its 5′ 2 and 3nucleotides largely abolished this activity (FIG. 12). Furthermore,miR-181a expression in T cells increased IL-2 production by two-foldcompared to the control (FIG. 2D). These results show that increasedmiR-181a expression augments TCR mediated T cell activation.

To quantify the effects of miR-181a on TCR signaling, we measured TCRsignal output in response to antigen stimulation at the single celllevel (FIGS. 1B&C). The TCR signal input is defined as the number ofantigenic peptide MHC complexes at the interface between T cells andAPCs, and the output is measured by the calcium concentration changes inthe T cell cytosol. In T cell blasts infected with control virus (thecontrol T cell blasts), ˜5 MCC peptides are needed to produce ahalf-maximal calcium response (EC50) (FIGS. 1B&D). This response isessentially identical to that of uninfected T cell blasts, suggestingthat viral infection did not cause discernable changes in TCR signaling.

In comparison, in the T cell blasts transduced with the miR-181aconstruct (the miR-181a T cell blasts), only ˜2 MCC peptides arerequired to reach the EC50 (FIGS. 1C&D), showing that miR-181aexpression increases T cell sensitivity by more than two-fold. Alsonotable is that, signal output in the miR-181a expressing T cells isabout 40% higher than that in the control T cells, as indicated by theplateau calcium flux (FIG. 1D). These observations demonstrate thatmiR-181a expression in mature T blast cells augments both the strengthand sensitivity of TCR signaling. The effects of miR-181a may beunderstated in this measurement since the MCC peptide is a strongagonist and may allow little room for further improvement. Indeed, amore dramatic increase in TCR signaling by miR-181a was observed whenthe miR-181a T cell blasts were challenged with MCC 102S—a weakantigenic peptide (FIG. 1E), showing that miR-181a expressionpotentiates the strength of TCR signal responses and quantitativelyaugments T cell sensitivity to both weak and strong agonist peptides.

MiR-181a Converts Antagonists into Agonists.

In addition to these quantitative changes in T cell sensitivity, we alsoexplored whether miR-181a could alter antigen discrimination and allow Tcells to respond to antagonists, which are antigenic peptide variantsthat are unable to stimulate TCR responses by themselves but block Tcell activation when they are presented together with a normallystimulatory concentration of agonist. Under a standard test condition,when the antagonist MCC 99R is present in large excess to the agonistMCC, TCR signaling is blocked in control T cell blasts, where no calciuminflux was detected (FIG. 2A). Interestingly, under the same conditions,MCC 99R cannot block the activation of the miR-181a T cell blasts,demonstrating that miR-181a overrides TCR antagonism (FIG. 2A). Since wehave shown that miR-181a expression in T cell blasts can augment the TCRresponse to agonists (FIG. 1), it was possible that this reversal of theantagonist function simply is the result of increased TCR responses tothe agonist beyond the ability of antagonist to block. However, when Tcells were challenged with antagonist alone, we found that theantagonist MCC 99R can stimulate a calcium response in miR-181a T cellblasts, demonstrating that miR-181a expression enables T cells torecognize MCC 99R as an agonist (FIG. 2B). MCC 99R stimulation resultedin a more than two-fold increase in the peak cytosolic calcium responseand sustained calcium elevation for more than 10 minutes, indicatingthat the antagonist induces a full-scale calcium response in these cells(FIG. 2C).

To further determine whether miR-181a expression converts antagonist MCC99R into a full agonist, we examined whether MCC 99R can stimulate IL-2production and T cell proliferation. In the miR-181a T cell blasts, MCC99R is able to stimulate production of the cytokine IL-2 (FIG. 2D) aswell as T cell proliferation (FIG. 2E), although somewhat weaker thanthe responses generated by MCC peptide in control cells. Moreover, thisdramatic functional switch is not limited to the MCC 99R antagonist.Similar results are seen with another antagonist, MCC 102G (FIG. 2F).Taken together, these results show that ectopic miR-181a expression in Tcell blasts not only quantitatively enhances T cell signaling strengthand T cell sensitivity to antigens, but it also enables T cell blasts torespond to antagonists.

MiR-181a Represses Multiple Negative Regulators in the TCR SignalingPathway.

To understand how miR-181a influences T cell reactivity to antigens, wefirst examined whether miR-181a regulates the expression of TCR or othersurface molecules that are known to play important roles in TCRsignaling strength and sensitivity. Interestingly, miR-181a expressionin T cell blasts does not change TCR density on the cell surface basedon antibody staining and flow cytometry analysis (FIG. 13A).Furthermore, miR-181a expression in T cell blasts causes no discernabledifference in surface CD4 expression (FIG. 13A), thus eliminating thepossibility that miR-181a augments T cell sensitivity by altering CD4coreceptor expression.

Interestingly, we did detect an increase in the costimulatory moleculeCD28 and a decrease in its antagonistic partner CTLA-4 on the miR-181a Tcell blasts (FIG. 13B). Modulating the expression of costimulatorymolecules by miR-181a seems to have a positive effect on TCR signalstrength as indicated by sustained calcium flux (FIGS. 13C&D), which mayhave contributed to the increase in the calcium response plateauobserved in FIG. 1D. However, miR-181a T cell blasts can still respondto MCC 99R while CD28 costimulation is inhibited by antibody blockade ofCD28 ligands (B7.1 and B7.2) on the APL's surface, indicating thatmiR181a's effect on costimulation does not contribute to the conversionof antagonists to agonists (FIG. 14).

Thus, these observations suggest that miR-181a is likely to modulate TCRsensitivity to antigens by controlling the intracellular TCR signalingmolecules. By challenging T cell clones bearing two distinct TCRs withtheir respective peptide agonist and antagonist, several studies haveshown that antagonists elicit negative signals that can actively repressthe agonist-induced responses from the other TCR. The tyrosinephosphatase SHP-1 has been proposed to be the negative feedbackregulator triggered by antagonists and the activation of ERK kinasesappears to override this suppression. However, our computationalanalysis does not shown any putative miR-181a binding sites in SHP-1gene. Furthermore, miR-181a expression in T cell blasts shows no changein SHP-1 expression at either protein (FIG. 3B) or RNA level. Thus,SHP-1 is not a direct target of miR-181a, suggesting that othercomponents of the TCR signaling pathway may contribute to TCRantagonism.

Since a number of tyrosine and serine phosphatases besides SHP-1 havebeen implicated in the suppression of TCR signaling, we examinedpotential miR-181a target sites in the phosphatases that are involved inTCR proximal signaling (non-receptor type tyrosine phosphatase, PTPNs)and ERK de-phosphorylation (dual specificity phosphatases, DUSPs). Wesearched for potential miR-181a pairing sites in both open readingframes (ORFs) and untranslated regions (UTRs) of the candidate genes. Wefound that the tyrosine phosphatases SHP-2 and PTPN22, and the ERKspecific phosphatases DUSP5 and DUSP6 each contain multiple putativemiR-181a pairing sites (FIG. 15). Those potential target sites with nearperfect seed pairing and/or the lowest free energy of binding wereselected for further validation using a luciferase reporter assay (FIG.15). Fusion luciferase reporters bearing predicted target sequences fromSHP-2, PTPN22, DUSP5, or DUSP6, respectively, were specificallyrepressed by miR-181a (FIG. 3A), but not by an miR181a mutant with its5′ second and third nucleotides altered (FIG. 3A) or miR-142.Furthermore, Western blot analyses revealed that SHP-2, PTPN22, DUSP5,and DUSP6 protein levels are quantitatively reduced by miR-181a, but notby an miR-181a mutant (FIG. 3B). As indicated by qPCR analyses, thereduction of target protein levels correlates well with the decreases incorresponding messenger RNA levels in the miR-181a T blasts, suggestingthat miR-181a can reduce the mRNA levels of the target genes. Theseresults demonstrate that miR-181a directly represses the expression ofmultiple phosphatases.

MiR-181a Expression Enhances Basal Activation of TCR SignalingMolecules.

Down-regulation of these phosphatases is likely to systematically reducenegative feedback regulation since the phosphatases targeted by miR-181aact at distinct steps in the TCR signaling pathway. PTPN22, a potentnegative regulator immediately downstream of TCR, can de-phosphorylateLck and ZAP70 at the activating Y394 and Y493 within the kinaseactivation loops. A gain-of-function variant of PTPN22 has been shown toreduce T cell sensitivity. Consistent with the role of PTPN22 as anegative regulator of Lck, we found an increase in Y394 phosphorylationin the activation loop of Lck in the miR-181a T cell blasts even beforestimulation (FIG. 4A).

DUSP5 and DUSP6, which are localized in the nucleus and cytosol,respectively, can specifically bind and inactivate ERK1/2 byde-phosphorylating the T202 and Y204 residues in the kinase activationloop. SHP-2 was found to mediate negative costimulatory signals elicitedby CTLA-4, but it has not been shown to play direct roles in TCRproximal signaling (FIG. 4E).

To examine how miR-181a may affect ERK1/2 activation, we measured theERK1/2 phosphorylation level before and after MCC 99R antagoniststimulation using intracellular antibody staining and FACS analysis. Tcell blasts were fixed at various time points after stimulation, stainedwith antibodies against the T202 and Y204 phospho-epitopes of the ERK1/2kinases, and analyzed by FACS to determine the ERK phosphorylationlevel. The miR-181a T cell blasts have a significantly higher level ofT202 and Y204 phosphorylated ERK proteins prior to stimulation (FIG. 4Bblue lines). Interestingly, the antagonist MCC 99R can stimulate ERKphosphorylation in miR-181a transfected T cell blasts or endogenouslyhighly expressed DP thymocytes (FIG. 23D), but not in control T cellblasts (FIG. 4B orange lines).

Furthermore, we examined whether miR-181a may alter the kinetics ofERK1/2 phosphorylation during T cell activation. T cell blasts wereactivated by CD3E cross-linking to avoid any contribution fromcostimulatory pathways. We noted that the miR-181a T cell blasts have asignificantly higher basal level of ERK phosphorylation beforestimulation and a slightly higher peak level after stimulation (FIG.4C). While both the control and miR-181a T cell blasts reached maximalERK phosphorylation within 15 minutes after stimulation, a delay in ERKdephosphorylation was observed in the miR-181a T cell blasts. Moreimportantly, the phosphorylation level of these cells returns to ahigher basal level when compared to controls (FIG. 4C, time points 15-60minutes). These data demonstrate that ERK phosphorylation is shifted toa higher basal level both before and after stimulation, suggesting thatmiR-181a induces decreases in phosphatase expression and acts to shiftthe equilibrium to higher steady-state levels of phospho-ERK. Thisincreased basal level of ERK phosphorylation has additional effects inpotentiating TCR proximal signaling. This is indicated by dramaticincreases in serine phosphorylation of Lck in miR-181a transduced cells.Co-expression of miR-181a and a DUSP6 gene without the miR-181a targetsites in T cell blasts restores DUSP6 expression to the normal level andreduces the basal Lck serine phosphorylation to the background levels,suggesting that the down-regulation of DUSP6 is directly responsible forthe increase in Lck serine phosphorylation.

While there are four major serine phosphorylation sites in Lck,activated ERK is responsible for Ser-59 phosphorylation underphysiological conditions. Previously, Germain and colleagues haveproposed that the positive feedback from ERK is crucial for agonistligands to overcome SHP-1 blockage and have shown that Ser-59phosphorylation of Lck can block SHP-1 recruitment. In agreement withthis observation, we noted a dramatic reduction in the recruitment ofSHP-1 to Lck before and after antagonist stimulation in miR-181a T cellblasts (FIG. 4E). It is also notable that restoring DUSP6 expression inthese cells results in a decrease in the basal level of Y394phosphorylation on Lck, suggesting that blocking SHP-1 recruitment toLck may also contribute to the increased basal level of thisphospho-tyrosine (FIG. 49A). These observations suggest an alternativemechanism in which antagonist-induced SHP-1 negative feedback can beovercome or reduced despite the fact that SHP-1 is not directly targetedby miR-181a. Collectively, it seems that the increased basal-level ofLck and ERK activation in the miR-181a T cell blasts reduces the amountof signal that is required for achieving full Lck and ERK activationupon antigen stimulation, thus reducing the activation threshold andincreasing signaling strength and T cell sensitivity to weak agonistsand antagonists (FIG. 8).

Furthermore, we examined whether miR-181a may alter the kinetics ofERK1/2 phosphorylation during T cell activation. T cell blasts wereactivated by CD3E cross-linking to avoid any contribution fromcostimulatory pathways. We noted that the miR-181a T cell blasts have asignificantly higher basal level of ERK phosphorylation beforestimulation and a slightly higher peak level after stimulation (FIG.4B). While both the control and miR-181a T cell blasts reached maximalERK phosphorylation within 15 minutes after stimulation, a delay in ERKdephosphorylation was observed in the miR-181a T cell blasts. Moreimportantly, the phosphorylation level of these cells returns to ahigher basal level when compared to controls (FIG. 4C, time points 15-60minutes). These data demonstrate that ERK phosphorylation is shifted toa higher basal level both before and after stimulation, suggesting thatmiR-181a induced decreases in phosphatase expression and activity shiftthe equilibrium to higher steady state levels of phospho-ERK. Thisincreased basal level of ERK phosphorylation has additional effects inpotentiating TCR proximal signaling. This is indicated by dramaticincreases in serine phosphorylation of Lck in miR-181a transduced cells(FIG. 4D). Co-expression of miR-181a and a DUSP6 gene without themiR-181a target sites in T cell blasts restores DUSP6 expression to thenormal level (FIG. 6A) and reduces the basal Lck serine phosphorylationto the background levels (FIG. 4D), suggesting that the down-regulationof DUSP6 is directly responsible for the increase in Lck serinephosphorylation. While there are four major serine phosphorylation sitesin Lck, activated ERK is responsible for Ser-59 phosphorylation underphysiological conditions.

We noted a dramatic reduction in the recruitment of SHP-1 to Lck beforeand after antagonist stimulation in miR-181a T cell blasts (FIG. 4E). Itis also notable that restoring DUSP6 expression in these cells resultsin a decrease in the basal level of Y394 phosphorylation on Lck,suggesting that blocking SHP-1 recruitment to Lck may also contribute tothe increased basal level of this phospho-tyrosine (FIG. 4A). Theseobservations suggest an alternative mechanism in whichantagonist-induced SHP-1 negative feedback can be overcome or reduceddespite the fact that SHP-1 is not directly targeted by miR-181a.Collectively, it seems that the increased basal-level of Lck and ERKactivation in the miR-181a T cell blasts reduces the amount of signalthat is required for achieving full Lck and ERK activation upon antigenstimulation, thus reducing the activation threshold and increasingsignaling strength and T cell sensitivity to weak agonists andantagonists.

Multi-Target Regulation by miR-181a is Crucial for miR-181a Function.

To determine whether one or all of the phosphatases regulated bymiR-181a are functionally relevant for its conversion of antagonistsinto agonists, we designed short hairpin siRNAs (shRNAs) to selectively‘knockdown’ SHP-1, SHP-2, DUSP5 and DUSP6 mRNA expression. Three shRNAconstructs were designed for each target gene and their efficacy insilencing their respective targets was validated by Western blotanalyses (FIG. 5A). In each case, we were able to obtain shRNAconstructs that can repress target gene expression more efficiently thanmiR-181a (FIGS. 3B&5A). We then expressed individual shRNAs in T cellblasts by viral transduction, isolated the infected cells to 90-95%purity by drug selection and magnetic bead selection, and challenged theinfected T cell blasts with APCs preloaded with MCC 99R (10 μM). Wedetermined the calcium response and then categorized the signal strengthusing the typical response of control T cells towards the MCC peptide asa reference. As shown in FIG. 5B, over 90% of the miR-181a T cell blastsyielded medium to strong responses when stimulated with MCC 99R, whereasless than 10% of the T cell blasts infected with shRNAs against SHP-2,control shRNAs (FIG. 5B), and control virus yielded similar responses,which represents the background levels. We noticed that shRNAs againstSHP-1 and DUSP6 do have modest effects, and about 25% and 38% of the Tcell blasts expressing shRNA against DUSP6 or SHP-1 yielded medium tostrong responses. However, both the peak values and the degree to whichcalcium signaling is sustained are reduced even in these reactive Tcells when compared to the response in the miR-181a T cell blasts.

Taken together, these data demonstrate that repressing individualphosphatases by shRNA is not sufficient to fully reproduce miR-181aphenotype in T cell blasts and miR-181a is much more efficient thanindividual shRNAs since it can down-regulate the expression of multiplephosphatases.

To evaluate whether down-regulation of individual miR-181a targets isnecessary for the increase in T cell sensitivity to antagonists, werestored the DUSP6 expression to normal levels in the miR-181a T cellblasts by co-expressing a DUSP6 gene that lacks the miR-181a targetsites (FIG. 6A). This resulted in a reduction in the basal level ofphospho-ERK (FIG. 21B, time point zero) and accelerated ERKdephosphorylation/inactivation as indicated by Phospho-Flow analysis(FIG. 6B, time points 10-60 mins). Most importantly, restoring DUSP6expression in this way completely abolishes the T cell reactivity to MCC99R (FIG. 6C, D, E). Similarly, restoring DUSP5 expression in thenucleus results in a dramatic reduction in the IL-2 production inducedby the MCC 99R antagonist, while it has little effect on cytosoliccalcium responses (FIGS. 6D&E), suggesting that wild type DUSP5 acts asa negative regulator controlling IL-2 production in the nucleus withlittle impact on the immediate TCR signaling. Interestingly, expressingand sequestering DUSP5 protein in the cytosol by nuclear localizationsignal mutation can largely resemble the TCR sensitivity shift caused byDUSP6 restoring (FIGS. 6D&E). These evidences collectively suggest thatthe cytosolic level of ERK activation is crucial for the initial TCRsignaling upon antigen recognition. In contrast, restoring SHP-2 doesnot change the basal level of Lck activation (FIG. 6A) or suppress therecognition of MCC 99R, although it does cause a modest reduction in TCRsignaling strength (FIG. 6D), suggesting that SHP-2 plays a minor rolein antigen discrimination. These results suggest that DUSP6, but notSHP-2, is one of the key players in the negative regulation of TCRsignaling.

Inhibition of miR-181a in Thymocytes Impairs Positive and NegativeSelection.

Our results clearly demonstrate that increasing miR-181a expressioninduces hypersensitivity in T cells (FIGS. 1&2), while inhibition ofthis miRNA dampens their sensitivity to antigens (FIG. 7).Interestingly, miR-181a expression is dynamically regulated during Tcell development, with immature DP cells having ˜10-fold more copies ofmiR-181a than their mature counterparts (FIG. 1A). Enhanced expressioncorrelates with heightened sensitivity towards pMHC ligands in DP cells,which is thought to be critical in ensuring proper positive and negativeselection, and shaping of the mature T cell repertoire. Consequently, wetested miR-181a function in DP cell selection using fetal thymic organcultures (FTOC) with an antagomir based loss-of-function approach.

We crossed 5C.C7 TCR transgenic mice onto an invariant chain knockout(li−/−) background to arrest thymocytes at the DP stage. Although amoderate increase in the DN cell population was observed, antagomir-181atreatment did not affect the viability of DP thymocytes in this culturesystem (FIG. 8A). Presenting exogenous 5C.C7 TCR antigens, such asagonist (MCC), weak agonist (MCC 102S) or antagonist (MCC 99R), caninduce efficient negative selection within 48 hours. Introducingantagomir-181a to these cultures results in a greater than 2-foldinhibition of negative selection (FIG. 8A). To examine the role ofmiR-181a in positive selection, day 15 fetal thymi from wild type 5C.C7embryos were used in this FTOC assay. These mice have normal invariantchain production and are capable of presenting endogenous peptideantigens, thus allowing positive selection. Dampening miR-181aexpression with the antagomir-181a reagent substantially impairspositive selection, reducing the number of mature CD4+ SP thymocyte by˜3-fold (FIG. 8B).

Does this inhibition of selection correlate with a deficiency in TCRsignaling? We verified this by observing the response of adult 5C.C7 DPthymocytes to in vitro antigen stimulation. In the presence ofantagomir-181a pretreatment, the responsiveness of these cells isdramatically diminished in a dose-dependent manner (FIG. 8C). Is thisantagomir-181a induced hyposensitivity related to the same molecularmechanism described for mature T cells? All MiR-181a targetedphosphatases are expressed in DP thymocytes and antagomir-181a treatmentelevates their mRNA level significantly. Coordinately, we observed asevere reduction of ERK activation in these antagomir-181a treated DPthymocytes both in basal level of ERK phosphorylation (FIG. 8D, timezero) and antigen-induced ERK phosphorylation (FIG. 8D, time 5′ to 60′).Collectively, these results demonstrate that antagomir-mediatedreduction of miR-181a expression in immature DP thymocytes attenuatestheir sensitivity to antigen and inhibits positive and negativeselection. Thus miR-181a is an intrinsic modulator of TCR sensitivityduring T cell development and differentiation.

Dampening Mature T Cell Sensitivity by miR-181a Inhibition.

The above results clearly show that that increasing miR-181a level in Tcell blasts by ectopic expression dampens the expression of multiplephosphatases in the TCR signalling pathway, reduces the TCR signallingthreshold, and results higher T cell sensitivity to antigens. To testwhether miR-181a may act as a ‘rheostat’ to tune T cell sensitivity, weexamined effects of decreasing miR-181a expression on T cell sensitivityto antigens.

Antagomirs—antisense oligos that silence miRNA expression in vivo—wereused to reduce miR-181a expression in T cells. We transfected eithernaïve T cells or mature blasts with an antagomir that targets miR-181a(antagomir-181a) and challenged antagomir treated cells with CH27 APCsloaded with MCC or MCC 102S at various concentrations. We then measuredthe calcium response by video microscopy (FIG. 7A) and IL-2 productionby ELISA (FIG. 7B) to determine the effects of antagomirs on T cellsensitivity to antigens. An antagomir-181 mutant (Mm-antagomir-181a)with a 6 nucleotide mismatch to the 5′ seed region of miR-181a was usedas a negative control. All antagomirs have a Cy3 label at the 5′-endwhich allows their transfection efficiencies to be monitored by FACS. Wewere able to achieve near 100% transfection efficiency and similarintensities for each oligo under the designated experimental conditions.We find that reducing miR-181a expression by antagomir treatmentsignificantly lowers naïve T cell sensitivity to the agonist MCC and theweaker agonist MCC 102S, as indicated by calcium flux and IL-2production (FIGS. 7A&B). Antagomir-181a also inhibits the increasedsurface expression of CD69 and CD5—two early T cell activationmarkers—upon antigen stimulation.

In contrast, the control antagomir has no effects on T cell sensitivityto antigens (FIGS. 7 A&B), showing that the effects of antagomir-181aare specific. Furthermore, reducing miR-181a expression also reduces Tcell sensitivity to antigens in the mature T cell blasts, albeit to alesser degree than that in the naïve T cells. The smaller reduction inantigen sensitivity in mature T cell blasts is probably because thatmiR-181a level in the mature T cell blasts (10 copies/cell) is muchlower than that in the naïve T cells (over 30 copies/cell) (FIG. 1A).Finally, maximum response towards agonist MCC can be induced at aloading concentration close to K_(d) in naïve T cells (FIG. 7A), whilemuch higher concentrations are required to elicit the maximal responsesin mature T cell blasts (FIG. 18B), suggesting that naïve T cells aremore sensitive to antigens. Collectively, these results demonstrate thattuning down miR-181a expression in naïve and mature T cells byantagomir-181a reduces T cell sensitivity to antigens and miR-181aexpression levels may positively correlate with T cell sensitivity.

Our studies demonstrate that TCR signaling strength and T cellsensitivity to antigens can be modulated at the post-transcriptionallevel by miR-181a. Further dissecting the targets regulated by miR-181ahas revealed that this change in T cell sensitivity requires thesimultaneous down-regulation of multiple negative regulators in the TCRsignaling pathway. Increasing miR-181a expression in T cell blastsresults in decreased phosphatase levels, which leads to an increase inthe amount of activated Lck and ERK kinases without antigenicstimulation and a reduction in the threshold required for T cellactivation. By reducing negative feedback mechanisms and potentiatingpositive ones, T cells now exhibit quantitatively and qualitativelydifferent responses to antigen stimulation. These findings have a numberof implications for the regulation of the adaptive immune response andthe biology of miRNAs. In particular, these data suggest that miR-181ais a T cell sensitivity rheostat. It is known that the same antigenicpeptides elicit distinct TCR signals and T cell responses in T cellpopulations at different developmental stages, suggesting that T cellsensitivity to antigens is intrinsically regulated. Properly tuning Tcell sensitivity at various development stages may be critical forregulating the development of tolerance and effector cell function.Interestingly, miR-181a expression is higher in some immature T cellpopulations that recognize low affinity selfantigens, such as DPthymocytes, but low in the more differentiated T cell populations thatare only reactive to high affinity foreign antigens and inert to lowaffinity self-antigens, such as Th1 and Th2 effector cells (FIG. 1A).

These observations reveal a positive correlation between miR-181aexpression and the T cell sensitivity to antigens, thus supporting thenotion that miR-181a may act as a rheostat to tune T cell sensitivityduring T cell development and maturation, since many of the miR-181atargets we identified are known to be functional components of TCRsignaling pathways in various T cell populations. These resultsdemonstrate that miRNAs represent a novel class of gene regulatorymolecules that can modulate T cell sensitivity.

Our findings provide new insights into the signaling pathways thatdetermine how TCRs sense quantitative differences in antigen affinityand elicit quantitatively and qualitatively different responses and alsohow such responses may be intrinsically tuned. These observationssuggest that the TCR and its proximal signaling molecules act as a“signal integrator” to sum up the positive and negative signals elicitedby antigen stimulation, thus determining the outcome of TCR engagement.It is known that in general, longer half-life pMHC ligands elicitstronger positive signals. We have found that the negative feedbacksignals in this pathway, controlled in part by multiple phosphatasesdownstream of TCR, play a key role in regulating TCR signaling andantigen discrimination, suggesting that they set the “excitationthreshold” for T cell activation and this “excitation threshold” islikely to be dominant. Supporting this, T cell blasts normally cannot beactivated by antagonist pMHCs (FIGS. 2 & 4), suggesting that theseligands cannot generate a sufficient degree of positive signals toovercome the “excitation threshold.” However, when the equilibrium isshifted towards a higher steady state of phosphorylated signalingintermediates (ERK1/2, Lck as shown above) by ectopically expressingmiR-181a in the T cell blasts (FIGS. 2 & 4), these ligands are nowstimulatory and weak agonists are now strongly stimulatory.

One would also predict that dampening these negative signals should leadto an increase in TCR signaling strength, since the degree of positivesignaling required for overcoming the “excitation threshold” is alsoreduced. Indeed, we have shown that antagonist MCC 99R, or weak agonist102S, or agonist MCC I-E_(k) complexes have increased signaling strengthin the miR-181a T cell blasts, as measured by calcium influx, albeit atquantitatively different levels (FIGS. 1 & 2). Our findings also suggesttwo venues that can be used to overcome this “excitation threshold” andto activate T cells. One is by reducing the “excitation threshold” suchthat it can be overcome by the otherwise insufficient positive signalsgenerated from the same antigens. Alternatively, weak positive TCRsignals can be potentiated so that the “excitation threshold” can beovercome. Finally, our finding that antagonists can be converted intoagonists demonstrates that even antagonists can bind to the TCR longenough to complete the entire TCR signaling cascade when the “excitationthreshold” is reduced. Interestingly, endogenous peptide-MHC complexesthat are known to synergize with agonist ligands still are notstimulatory to miR-181a transfected T cell blasts (FIG. 2D, E). Theaffinities and half-lives of these ligands for 5C.C7 TCR are not known,but they are probably considerably less stable than the antagonistligands.

Many biological processes are controlled at the system level bycoordinated regulation of networks of genes. Specifically, TCR signalingand antigen recognition are controlled by sequential phosphorylation andde-phosphorylation events in a spatially and temporally ordered manner.T cells express more than 40 different tyrosine phosphatases and otherknown or unknown negative regulators of TCR signalling. There aremultiple phosphatases for each of the key kinases, such as Lck, ZAP70,ERK, etc. Tuning a T cell's “excitation threshold” presents a particularchallenge because of the many signaling molecules that seem toconstitute the threshold. It may require the coordinate regulation ofmultiple negative regulators which share little or no sequence homology.Our findings clearly demonstrate that this task can be carried out veryefficiently by a single miRNA, which can regulate multiple target genes,but not by a shRNA, which is designed to target one of the miRNAtargets. This is consistent with the notion that each miRNA can regulatehundreds of target genes. Collectively, our findings suggest that miRNAsare evolutionarily selected gene regulatory molecules that can carry outintegrated biological functions by regulating gene networks.

Materials and Methods

Mice, Cells and Peptides.

5C.C7 αβ TCR transgenic mice on the B10.BR background were obtained fromTaconic. 5C.C7 li^(−/−) mice were obtained by crossing 5C.C7 ontoli^(−/−) B10.BR mice. All mice were bred and maintained at the StanfordUniversity Department of Comparative Medicine Animal Facility inaccordance with National Institutes of Health guidelines. T cells wereharvested from the lymph nodes of 5C.C7 mice and primed with 10 μM MCCpeptide. A day after priming, T cells were transduced with retroviralmiRNA expressing constructs. Infected T cell blasts were first subjectedto blasticidin (12.5 μg/ml, Invitrogen) selection for two days startingat 36-hour post-infection, further enriched by density gradientcentrifugation with Histopaque-1119 (Sigma-Aldrich), and finallypurified based on H-2K^(b) expression of the infected T cell blasts bymagnetic bead sorting according to the manufacturer's protocol(Biotinylated anti-H-2K^(b), 10 μg/ml, BD Pharmingen; CELLection biotinbinder kit, Dynal Biotech). With this procedure, infected T cell blastswere enriched to at least 95% purity based on FACS analyses. Antigenicpeptide variants used in this study were the agonist MCC SEQ ID NO:31(ANERADLIAYLKQATK), weak agonist MCC 102S SEQ ID NO:32(ANERADLIAYLKQASK), antagonist MCC 99R SEQ ID NO:33 (ANERADLIAYLRQATK)and MCC 102G SEQ ID NO:34 (ANERADLIAYLKQAGK), and null peptide MCC 99ASEQ ID NO:35 (ANERADLIAYLAQATK). Variations in residues are underlined.Peptide-loaded CH27 cells, a mouse B lymphoma cell line, were used asantigen presenting cells in this study.

Plasmid Constructs.

The original retroviral miRNA expression construct was modified toincorporate a truncated H-2K_(b) surface marker and a blasticidin drugresistance gene to allow for magnetic bead assisted sorting and drugselection (FIG. 26?). These marker genes are driven by the PGK promoterand transcribed as a bicistronic message, with the truncated H2K_(b)gene placed after the PGK promoter and the blasticidin resistance geneafter the EMCV IRES (internal ribosomal entry site). miRNA geneexpression is driven by the human H1 pol III promoter. The truncatedH-2K_(b) selection marker is non-functional since it is devoid of acytoplasmic domain and is of a different MHC haplotype than the T cellsin 5C.C7 transgenic mice (H-2K_(k)). miR-181a^(mut) was generated byaltering the 5′ second and third nucleotides of the mature miR-181a(from (SEQ ID NO:36) 5′AACAUUCAACGCUGUCGGUGAGU3′ to (SEQ ID NO:37)5′AUAAUUCAACGCUGUCGGU GAGU3′, nucleotide changes are underlined).

Compensatory mutations were introduced to the miR-181a* strand topreserve the secondary structure of pre-miR181a (FIG. 27). MutantmiR-181a can be properly expressed and processed as indicated byNorthern blot analyses.

The basic firefly luciferase and lin-41 3′UTR fusion were cloned into aMSCV (murine stem cell virus) retroviral vector (FIG. 11B). PutativemiR-181a target sequences were PCR amplified from a mouse cDNA libraryand subcloned to replace the lin-41 3′UTR in the basic reporterconstruct. Target regions amplified and corresponding PCR primers arelisted:

SEQ ID (1) SHP-2-t1 (NM_011202.2: 5312 to 5533, 3′ UTR) 38 Sense: 5′AGAGTCACTCGAGTTAATACACTTTAGTGTCAAGA 3′ 39 Antisense: 5′ATACATCACGCGTCAAGAAAATGATTTTATTCTA 3′(2) DUSP6-t1 (NM_026268.1: 2511 to 2748, 3′ UTR) 40 Sense: 5′AGAGTCACTCGAGTAACTTCAGCTGTGCTAAACA 3′ 41 Antisense: 5′ATACATCACGCGTTAATAAATTCCAGCTCAA AAC 3′(3) DUSP5-t1 (XM_140740: 572 to 979, ORF) 42 Sense: 5′AGAGTCACTCGAGACTGGCAGAAGCTGCGGGAGGA 3′ 43 Antisense: 5′ATACATCACGCGTCCACGGGGATCCACTTGTAGT 3′(4) DUSP5-t2 (XM_140740: 2141 to 2485, 3′ UTR) 44 Sense: 5′AGAGTCACTCGAGCATGGTATCTCTCTAAAGCAC3′ 45 Antisense: 5′ATACATCACGCGTAAAACAAACCAACCAAGCAAC 3′.(5) PTPN22-t-1 (NM_008979.1: 266 to 561, ORF) 46 Sense: 5′AGAGTCACTCGAGCCCAAGAATATCAAGAAAAACAGATACAAGG 3′, 47 Antisense: 5′ATACATCACGCGT TGCGTTTCTCCTGGTTCGGCCCA 3′;(6) PTPN22-t-2 (NM_008979.1: 932 to 1618, ORF) 48 Sense: 5′AGAGTCACTCGAGCAAACTCAGGAACAGTACGAAC 3′, 49 Antisense: 5′ATACATCACGCGT ATTCAGCTCTTCTGAAGAAACA 3′

To selectively restore miR-181a target expression in the miR-181a T cellblasts, a construct that simultaneously expresses miR-181a and theDUSP6, DUSP5 or SHP-2 coding regions were constructed (FIG. 26C). Themouse DUSP6, DUSP5 and SHP-2 coding regions were PCR amplified from acDNA library generated from day 6 5C.C7 T cell blasts and cloned intothe miR-181a expression vector (FIG. 26C) to replace the H-2K_(b) gene.

Antibodies and Fluorescent Reagents.

α-mouse PTPN22 polyclonal antibody was a kind gift from Dr. A. Chan andDr. K. Hasegawa (Genentech). PE-streptavidin, PECy5-streptavidin,biotin-α-CD3ε, biotin-α-CD28, biotin-α-H-2K_(b), biotin-α-IL-2,α-CD16/32, α-B7.1, α-B7.2, α-IL-2, FITC-α-CD4, PE-α-CTLA4, α-Lck PY505,PE-α-phospho-ERK1/2 and their isotype controls were from BD Pharmingen.Biotin-syrian hamster IgG control and FITC-conjugated Donkey anti-RabbitIgG were from Jackson ImmunoResearch. Streptavidin was from Prozyme. Forcross-linking experiments, azide was dialyzed away before use. α-Lck(3A5, for immunoprecipitation), α-SHP-2 (polyclonal) and α-phosphoserine(polyclonal) were from Upstate/Chemicon.

-DUSP6 (polyclonal), α-actin and α-Lck (polyclonal for immunoblotting)were from Santa Cruz Biotech. α-PY416 of Src family (PY394 of Lck) andanti-ppERK (T202/Y204) rabbit monoclonal antibody (197G2) were from CellSignaling Technology. α—DUSP5 was from ABcam. α-SHP-1 (polyclonal) wasfrom R&D Systems. The calcium indicator Fura-2-AM was purchased fromMolecular Probes.

Quantitative RT-PCR for miRNA Expression Analysis.

The ABI TaqMan miRNA assay was used to measure miR-181a expression invarious T cell populations. Purified T cells were spiked with asynthetic miRNA standard at a fixed ratio of pmol per cell. Total RNAsamples were then prepared using Trizol reagents. MiRNA expression ineach cell population was determined using standard curve methodsfollowing the ABI TaqMan miRNA quantitative PCR protocol. QuantitativePCR for targets expression analysis. A two step qPCR approach was takento quantify the mRNA level of various genes in this study. Total RNAwere extracted from control or miR-181a virus infected day 6 T cellblasts with PureLink™ RNA extraction kit (Invitrogen) and the firststrand cDNA synthesis was performed with Superscript III system(Invitrogen). Using these single strand cDNA as template, quantitativePCR assays were performed with Platinum SYBR Green qPCR Supermix-UDG(Invitrogen) on an iQ5 qPCR machine (Bio-Rad). For each experiment,β-actin was used to normalize the amount of cDNA input. The PCR primersare: 1) for PTPN22, sense primer: 5′ GCAGTGGGACATCTGAAATGAAGAGC 3′ (SEQID NO: 59), antisense primer: 5′ CGGCTTGGGCCTGTATACAGTCCT 3′ (SEQ ID NO:60); 2) for SHP-2, sense primer: 5′ GTTAAGCAAGCTGGCTGAGCCAC 3′ (SEQ IDNO: 61), antisense primer: 5′ CTGGAGTAGAGCTTGTCCGACCTTA 3′ (SEQ ID NO:62); 3) for SHP-1, sense primer: 5′ CAGGGACGTGACAGTAACATCCC 3′ (SEQ IDNO: 63), antisense primer: 5′CAGGTCCCCATTGTCTAGTGGG 3′ (SEQ ID NO: 64);4) for DUSP5, sense primer: 5′ GCCCGCGGGTCTACTTCCTTAAA 3′ (SEQ ID NO:65), antisense primer: 5′ ATTTCAACCGGGCCACCCTGG 3′ (SEQ ID NO: 66); 5)for DUSP6, sense primer: 5′ TCCCTGAGGCCATTTCTTTCATAGATG 3′ (SEQ ID NO:67), antisense primer: 5′ GCAGCTGGCCCATGAAGTTGAAGT 3′ (SEQ ID NO: 68) 6)for β-actin, sense primer: 5′ TCTAGACTTCGAGCAGGAGATG 3′ (SEQ ID NO: 69),antisense primer: 5′ CTAGGAGCCAGAGCAGTAATCT 3′ (SEQ ID NO: 70).

Multi-Channel Time-Lapse Microscopy.

Calcium imaging and synaptic peptide quantification were performed on aZeiss Axiovert-100TV station equipped with a CoolSNAP_(HQ) CCD camera(Roper Scientific). Calcium dye Fura-2-AM (5 μg/ml) was loaded into day6 5C.C7 T cells at room temperature for 30 minutes. Imaging experimentswere performed on a humidified stage at 37° C. and 5% CO₂. The recordingwas controlled by MetaMorph software (Universal Imaging Corp). Signalsfrom Fura-2 (ex 340 nm and 380 nm, em 510 nm/80 nm) were collected at 10or 15 second intervals for up to 15 minutes and PE labelled peptideswere imaged (ex 555 nm/28 nm, em 617 nm/73 nm) at variable time points.For each field, 21 stacks of PE images were taken at 1

m increments and the 3D images were reconstructed to measure theintegrated fluorescence intensity. Image analysis was performed usingMetaMorph Software Suite. The data points were pooled from four batchesof primary cell preparation. For calcium dynamics and concentrationintegration analysis, in activated T cells, time zero was defined as thetime point prior to the first 20% increase of ratioed fluorescentintensity, then the basal line (value=1.00) was drawn by averaging theintensity before time zero. In inactive T cells, time zero wasarbitrarily assigned as the T:APC contact point observed in the DICchannel. The integrated value of cytosolic calcium elevation wasgenerated by summing up the changes in relative calcium concentration ateach time point within the first 5 minutes of T cell calcium response.

Phospho-Flow Analysis.

Phospho-Flow technology was used to monitor T202 Y204 phosphorylation inERK1/2 (ppERK). Briefly, T cell blasts infected with miR-181a expressingvirus (GFP positive) were stimulated with APCs loaded with eitherantigenic peptides or with anti-CD3E cross-linking, and fixed with 2%paraformaldehyde at room temperature for 20 minutes. After washes withice-cold FACS buffer (PBS pH 7.4, 2 mM EDTA, 2% FBS), T cell blasts wereblocked with anti-CD16/CD32 (10 μg/ml) for 15 minutes on ice and stainedwith fluorescent antibodies against the cell surface markers CD4, CD28,etc. After being washed three times with FACS buffer, T cell blasts weresuspended in 90% ice-cold methanol and kept on ice for 30 minutes toallow for permeabilization. One million permeabilized cells were furtherblocked by anti-CD16/CD32 and species-matched serum, stained withphosphorspecific ERK antibody, and analyzed by FACS (Cytomics FC500,Beckman Coulter). FACS data was analyzed with FlowJo software (TreeStar, Inc). The ppERK staining results were repeated with an indirectstaining approach as reported by Altan-Bonnet et al (Altan-Bonnet andGermain, 2005). In this method, T cell blasts were stained with antippERK rabbit monoclonal antibody (Cell Signaling Technology), thenfollowed by donkey Cy5-anti-rabbit IgG staining (Jackson ImmunoResearch)and FACS analysis.

Luciferase Reporter Assay for Target Validation.

NIH-3T3 cells stably expressing miR-181a and miR-181a mut were generatedby viral transduction and multiple rounds of blasticidin selection andthen transfected with 0.1 μg of firefly luciferase reporter vectortogether with 0.025 μg of control Renilla luciferase control vectorusingFuGene 6 reagents (Roche). Cells were lysed at 48 or 72 hours aftertransfection and analyzed for firefly and Renilla luciferase activitiesusing the Dual-Luciferase Assays (Promega) on a Veritas™ MicroplateLuminometer.

Fetal Thymic Organ Culture.

Thymi were dissected from day 15 embryos of 5C.C7 αβ TCR mice or day 17embryos of 5C.C7 αβ TCR li^(−/−) mice. Fetal thymi were cultured on 0.8micron filters (Millipore) and MF support pads (Millipore) floated onRPMI culture medium. Antagomirs were added to thymi at a finalconcentration of 50 μg/ml on day 0 of culture, antigenic peptides wereadded on day 1, and single cell suspensions were prepared for FACSanalysis on day 3-5.

Antagomir and Treatment.

Antagomirs were synthesized as described (Krutzfeldt et al., 2005). Thesequences are as shown in Example 3. All nucleotides used in synthesisare 2′-OMe-modified. Subscript ‘s’ represents a phosphorothioatelinkage; “Cy3” indicates Cy3 dye label at the 5′ end of the oligo;“Chol” represents cholesterol linked through a hydroxyprolinol linkage.For naïve T cell transfection, cells were cultured for 16 hours in thepresence of 5 ng/ml IL-7 and 50 μg/ml Ant181 or Mm Ant181; for DPthymocyte transfection, cells were cultured in RPMI medium for 12 hoursin the presence of various amount of antagomir.

Example 3 Synthesis of Antagomirs

The single-stranded RNAs and modified RNA analogues (anatgomirs) weresynthesized using U, C^(Bz), A^(Bz) and G^(iBu) with 2′-O-methyl sugarmonomers using β-cyanoethyl phosphoramidite chemistry and standardoligonucleotide synthesis protocols unless otherwise specified (Ref:Damha, M. J. & Ogilvie, K. K. Oligoribonucleotide synthesis. Thesilyl-phosphoramidite method. Methods Mol. Biol. 20, 81-114 (1993). Themodifications used in this study are listed in Table 2. Quasar-570(Q570, Cy3) and Quasar-570 (Q670, Cy5) phosphoramidite from BiosearchTechnologies was coupled to the 5′-terminal under standards solid phasephosphoramidite synthesis conditions to obtain fluorophore taggedantagomirs, 2, 6-10 and mm-antagomirs 11-14 shown in Table 2 and FIG.19. Extended 15 min coupling of quasar-570 phosphoramidite at aconcentration of 0.1M in CH₃CN in the presence of5-(ethylthio)-1H-tetrazole activator followed by standard capping,oxidation and deprotection afforded labeled oligonucleotides. The Q570conjugated sequences were HPLC purified on an in-house packedRPC-Source15 reverse-phase column. The buffers were 20 mM NaOAc in 10%CH₃CN (buffer A) and 20 mM NaOAc in 70% CH₃CN (buffer B). Fractionscontaining full-length oligonucleotides were pooled together anddesalted. Integrity of the compounds were established by analyticalHPLC, CGE and ES LC-MS. For duplex generation, equal molar mounts ofmiR-122 and antagomir were heated in 1×PBS at 95° C. for 5 min andslowly cooled to room temperature.

TABLE 2 Antagomirs and mm-antagomirs for various miRNA targetsAntagomir/ SEQ mm-Antagomir SEQUENCE TARGET ID NO 1oAsoCsoUoCoAoCoCoGoAoCoAoGoCoGoUoUoGoAoAoUsoGsoUsoUs-Chol miR-181a 50 2Cy3-oAsoCsoUoCoAoCoCoGoAoCoAoGoCoGoUoUoGoAoAoUsoGsoUsoUs-Chol miR-181a50 3 oCsoCsoCoCoUoAoUoCoAoCoAoAoUoUoAoGoCoAoUsoUsoAsoAs-Chol miR-155 514 oGsoUsoAoGoUoGoCoUoUoUoCoUoAoCoUoUoUsoAsoUsoGs-Chol miR-142-5p 51 5oCsoCsoAoUoAoAoAoGoUoAoGoGoAoAoAoCoAoCoUsoAsoCsoAs-Chol miR-142-3p 52 6Cy5-soAsoCoUoCoAoCoCoGoAoCoAoGoCoGoUoUoGoAoAoUsoGsoUsoUs-Chol miR-181a50 7 Cy5-soAsoCoUoCoAoCoCoGoAoCoAoGoGoUoUoGoAoAoUsoGsoUsoUs-CholmiR-181c 53 8Cy5-soCsoCoCoCoUoAoUoCoAoCoAoAoUoUoAoGoCoAoUsoUsoAsoAs-Chol miR-155 54 9Cy5-soGsoUoAoGoUoGoCoUoUoUoCoUoAoCoUoUoUsoAsoUsoGs-Chol miR-142-5p 5110  Cy5-soCsoCoAoUoAoAoAoGoUoAoGoGoAoAoAoCoAoCoUsoAsoCsoAs-CholmiR-142-3p 52 11 Cy3-soAsoCoUoCoAoCoCoGoAoCoAoGoCoGoUoUoUoUoUoAsoUsoAsoUs-CholMM-mirR181a 55 12 Cy3-soAsoCoUoCoAoCoCoGoAoCoAoGoGoUoUoGoAoAoUsoGsoUsoUs-Chol MM-miR-181c56 13  Cy3s-oAsoCoAoAoAoCoAoCoCoAoUoUoGoUoCoAoCoAoCoUsoCsoCsoAs-CholmiR-122 57 14 Cy3s-oAsoCoAoCoAoCoAoAoCoAoCoUoGoUoCoAoCoAoUoUsoCsoCsoAs-CholMM-miRr-122 58 Note: Modifications are as follow: A) oN = 2′-O-methyl B)s = PS linkage C) Cy3 = Quasar 570 dye D) Cy5 = Quasar 670 dye

The compositions and procedures provided in the description can beeffectively modified by those skilled in the art without departing fromthe spirit of the invention embodied in the claims that follow.

This application specifically incorporates by reference U.S. ProvisionalApplication Ser. No. 60/854,407, filed Oct. 24, 2006, U.S. ProvisionalApplication Ser. No. 60/873,764, filed Dec. 8, 2006, and U.S.Provisional Application Ser. No. 60/901,177, filed Feb. 12, 2007.

1.-33. (canceled)
 34. A method of treating a disorder or disease, themethod comprising: altering the activity of miR-181a in T cells of apatient suffering from a disorder, wherein the T cell receptor (TCR)signaling threshold and T cell sensitivity to antigen is altered,wherein the disorder is selected from an atopic disorder, an autoimmunedisorder, infectious disease and cancer.
 35. The method according toclaim 34, wherein said atopic disorder is asthma.
 36. The methodaccording to claim 34, wherein the disease or disorder is cancer andwherein T cell sensitivity to specific tumor antigens is altered. 37.The method according to claim 34, wherein miR-181a activity isdown-regulated and said TCR signaling threshold is raised.
 38. Themethod according to claim 34, wherein miR-181a activity is up-regulatedand said TCR signaling threshold is lowered.
 39. A method for thediagnosis of a predisposition to a T cell mediated immune dysfunction,the method comprising: detecting an alteration from wild-type ofmiR-181a sequence or expression.
 40. The method according to claim 39,wherein miR-181a activity is down-regulated and said TCR signalingthreshold is raised.
 41. The method according to claim 39, whereinmiR-181a activity is up-regulated and said TCR signaling threshold islowered.
 42. A method of reducing undesirable T cell activity in anindividual, the method comprising: reducing the activity of miR-181a inperipheral T cells of the individual by administering a modifiedoligonucleotide that is complementary to miR-181a, wherein theoligonucleotide is at least 12 but not more than 25 nucleotides inlength and has no more than 2 mismatches over its length compared to anequal length portion of miR-181a; and thereby raising T cell receptorsignaling threshold and decreasing T cell sensitivity to antigen. 43.The method of claim 42, wherein said modified oligonucleotide comprisesa cholesterol conjugate.
 44. The method of claim 42, wherein saidmodified oligonucleotide comprises one or more phosphorothioatelinkages.
 45. The method of claim 42, wherein said modifiedoligonucleotide comprises one or more sugar modifications.
 46. Themethod of claim 42, wherein said modified oligonucleotide has no morethan 1 mismatch over its length compared to an equal length portion ofmiR-181a.
 47. The method of claim 42, wherein said modifiedoligonucleotide is fully complementary over its length compared to anequal length portion of miR-181a.
 48. The method of claim 42, whereinsaid modified oligonucleotide is at least 20 but not more than 25nucleotides in length.